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Abstract 
Breast cancer is the most common cancer type among women in Norway and 2839 patients 
were diagnosed in 2010. Breast cancer is a genetic disease where both germline and somatic 
mutations lead to cancer development and progression. Each breast cancer patient has a 
unique genomic and phenotypic background. Alterations and dysregulation of signaling 
pathways like PI3K/AKT among others, have been reported to have an important impact on 
treatment response and disease progression. More knowledge is needed about the deregulated 
genes and their mechanisms in breast cancer. The interleukin-3 (IL-3)-dependent pro 
lymphoid B-cell line Ba/F3 can be used to study the oncogenic potential of selected cancer 
genes. Here, our aim was to establish this method to be used in our laboratory. Expression of 
an oncogenic allele decides if the Ba/F3 cells grow in absence of IL-3 or not. Three missense 
mutations, TP53 K120E, TP53 H179R and PIK3CA P110 S405F, were tested. Plasmids 
carrying the mutated genes were constructed by in vitro site-directed mutagenesis. The 
validation of the mutagenesis was performed using Sanger sequencing. Plasmids carrying the 
mutated genes and control plasmids were transfected by electroporation, where the 
permeability of the cells was increased by an electric field and the plasmids were transferred 
into the Ba/F3 cells. After transfection, the Ba/F3 cells were cultured in the presence of IL-3 
and Blasticidin for 10 days, to select for transfected cells. The parental cells died as they were 
not resistant against Blasticidin, whereas the Ba/F3 cells with plasmids survived. The 
transfected cells were further cultured in the absence of IL-3 and the cultures were 
microscopically evaluated and photographed every week. Microscopic evaluation of 
transfected Ba/F3 cell lines showed oncogenic mutations for TP53 H179R, PIK3CA P110 
S405F and the positive control PIK3CA P110 E545K. However, TP53 K120E was non-
oncogenic. The cell viability was determined with Trypan blue staining and cell viability 
assay. According the viability assay, the cells were not viable indicating that we were 
unsuccessful in creating stable cell lines. In summary, we have successfully established the 
Ba/F3 method in our laboratory and tested the oncogenic potential of known mutations in the 
TP53 and PIK3CA genes. 
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Sammendrag 
Brystkreft er den mest vanlige krefttypen blant kvinner i Norge og 2839 pasienter ble 
diagnostisert i 2010. Dette er en genetisk sykdom hvor både arvelige og somatiske mutasjoner 
kan føre til kreftutvikling. Hver brystkreft pasient har en unik genetisk og fenotypisk 
bakgrunn. Endringer og dysregulering av signalveier som PI3K/AKT blant flere, har vært 
rapportert å ha en viktig innvirkning på behandlingsrespons og sykdomsutvikling. Mere 
kunnskap er nødvendig om deregulerte gener og deres mekanismer i brystkreft. En 
interleukin-3 (IL-3) avhengig pro lymfoid B-cellelinje Ba/F3 kan brukes for å studere 
onkogenisk potensial av utvalgte gener. Målet var å etablere denne metoden i vårt 
laboratorium. Ekspresjonen av et onkogenisk allel bestemmer om Ba/F3 cellene vokser i 
fravær av IL-3 eller ikke. Tre missens mutasjoner TP53 K120E, TP53 H179R og PIK3CA 
P110 S405F ble testet. Plasmider som bærer mutante gener ble konstruert med in vitro punkt 
mutagenese. Sanger sekvensering ble utført for å validere mutagenesen. Plasmider med 
mutante gener og kontroll plasmider ble transfektert med elektroporering, hvor 
cellepermeabiliteten på Ba/F3 cellene økte under påvirkning av høy spenning og plasmidene 
ble overført inn i cellene. Etter transfeksjonen ble Ba/F3 cellene dyrket med IL-3 og 
Blasticidin i 10 dager for å få selektert for transfekterte celler. De parentale cellene døde fordi 
de ikke var resistente mot Blasticidin, mens Ba/F3 celler med plasmider overlevde. De 
transfekterte cellene ble dyrket videre uten IL-3 i mediet og cellekulturene ble mikroskopisk 
evaluert og fotografert hver uke. Mikroskopisk evaluering av de transfekterte Ba/F3 
cellelinjene viste onkogeniske mutasjoner for TP53 H179R, PIK3CA P110 S405F og positiv 
kontroll PIK3CA P110 E545K. TP53 K120E var ikke onkogenisk. Celleveksten ble bestemt 
ved Trypan blå farging av cellene og celleviabilitetsanalyse. I følge denne analysen var 
cellene døde og dette indikerte at vi ikke lyktes med å etablere stabile cellelinjer. Som en 
oppsummering så var etableringen av Ba/F3 metoden i vårt laboratorium vellykket, og vi fikk 
testet det onkogeniske potensialet til kjente mutasjoner i TP53 og PIK3CA genene.    
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Aim of the study 
The aim of this master project was to establish a Ba/F3 method in our laboratory. The Ba/F3 
cell line is a murine IL-3 dependent pro lymphoid B-cell line and can be used to study the 
oncogenic potential of selected cancer gene mutations. Furthermore, we aimed to study the 
oncogenic potential of three mutations; two mutants in the TP53 and one mutant in the 
PIK3CA gene. After transfection of parental Ba/F3 cells, the expression of oncogenic alleles 
leads to cell growth in the absence of IL-3, and cell viability can be measured. By using this 
functional assay we can characterize whether gene mutations are oncogenic or non-oncogenic. 
This model system can be useful as a tool in assessing the oncogenic potential of cancer gene 
mutations, the downstream signaling of these, as well as in testing whether the mutations are 
druggable. 
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1. Introduction 
1.1. Cancer 
Cancer is a leading cause of death worldwide with an estimate of 12,7 million new cases and 
7,6 million cancer deaths in 2008. Aging and growth of the world population are increasing. 
Changes in lifestyle added to pre-existing risk factors will increase the number of cancer 
incidence in many developing countries (1).  
 
Cancer is the most frequent genetic disease (2) and studies on cancer patient materials show 
clonal accumulations of somatic mutations over time (3). Over the past few decades, 
development of new sequencing- and molecular profiling methods has revealed the 
complexity of alterations in the cancer genomes.  
 
Hanahan and Weinberg have characterized human cancer and its development (4;5). The six 
hallmarks of cancer are resisting cell death, inducing angiogenesis, enabling replicative 
immortality, activating invasion and metastasis, evading growth suppressors, and sustaining 
proliferative signaling. These characteristics enable tumors to growth and metastasize. 
Underlying these hallmarks are inflammation and genomic instability. 
 
In 2011, two emerging hallmarks, reprogramming energy metabolism and evading immune 
destruction, were also included in the characterization of cancers (Figure 1) (5). Tumor tissue 
also comprises of normal cells such as fibroblast and endothelial cells which interact with 
each other. These cells among others are part of the tumor microenvironment and active 
participants in tumorigenesis by providing growth signals, which affect the proliferation. 
Another contribution from stroma is the supply of signals to resist apoptosis to increase the 
survival of tumor cells. 
 
Cancer cells can be affected by altered stress level resulting in phenotypic stress such as 
metabolic, proteotoxic, mitotic, oxidative and DNA damage stress (6). These phenotypes are 
not initiating tumorigenesis but characterize many tumor types. They are not unique to cancer 
cells only, but can also be observed in other conditions, such as chronic inflammation.   
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Figure 1. Enabling characteristics and emerging hallmarks of cancer.  
The six hallmarks of cancer are resisting cell death, inducing angiogenesis, enabling replicative immortality, 
activating invasion and metastasis, evading growth suppressors and sustaining proliferative signaling (grey text 
boxes). Underlying these hallmarks are tumor-promoting inflammation and genomic instability and mutation 
(blue and orange text boxes). The two emerging hallmarks are deregulating cellular energetics and avoiding 
immune destruction (purple and violet test boxes). The figure is modified from Hanahan and Weinberg (4;5). 
 
1.2. Breast Cancer 
Breast cancer is the most frequently diagnosed cancer among women worldwide. In 2008,  
1,38 million new cancer cases were diagnosed (1). The disease caused over 400 000 deaths 
yearly (7). Breast cancer is a heterogenic disease (8). The subchapters below address the 
aspects of heterogeneity on the epidemiological, clinical, and the molecular level.   
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1.2.1. Survival, incidence and mortality of breast cancer in Norway 
The survival of breast cancer has increased as a result of early diagnoses, improved treatment 
strategies and better surgery. Almost 90 % of the breast cancer patients are alive five years 
after diagnosis without any sign of relapse of the disease, (Figure 2) (9). In 2010, the number 
of cases was 2839 and the relative mortality was 673 (9).   
 
 Figure 2. Trends in the incidence, mortality and 5-years survival proportions of breast cancer in Norway. 
The survival has increased in the last two decades (9).   
                
1.2.2. Genetic risk factors 
Genetic alterations associated with developing breast cancer can be either inherited or 
acquired. Out of the total number of breast cancers  only 5-10% represent the familial type 
(10), as illustrated in Figure 3. These patients have a mutation of the BRCA1 or BRCA2 tumor 
suppressor genes. Patients with these mutations are hereditarily predisposed for breast cancer 
and have a high risk of developing the disease (11). Only 20 % of the familial types have 
mutations in BRCA1 and BRCA2 genes. A large proportion of the familial breast cancers have 
unknown familial predisposing genes and may be due to combinations of genetic variants of 
different loci (10).  
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Figure 3. Diagram showing the proportion of familial breast cancer among all breast cancer.  5-10% of 
total number of all breast cancers represent the familial type (right) and the genes involved are BRCA1/2 .These 
two genes are mutated in only 20 % of the familial cancers. A large proportion of the familial breast cancers 
have unknown familial predisposing genes (left) (10).  
 
1.2.3. Environment and lifestyle factors 
The high incidence rate of breast cancer is attributed to lifestyle factors. These include 
physical inactivity, hormone replacement therapy (HTR), overweight or obesity, alcohol 
consumption and dietary habits (12). All these factors may affect not only the incidence, but 
also mortality and treatment outcomes. For example, breast cancer patients with obesity have 
been found to have a poorer prognosis (13). 
  
Dense breast tissue is also a risk factor for breast cancer.  Mammographic density is 
characterized by increased number of breast epithelial cells and stromal tissue (14). 
Reproductive parameters such as low parity, late age at first pregnancy (>35 years), late 
menopause (>55 vs <45 years) and early menarche (<12 vs 16 years) are also risk factors 
(12).  
 
More than 80 % of breast cancer patients are over 50 years old. A possible reason is the 
exposure to endogenous and environmental carcinogens, which lead to accumulation of gene 
mutations over time (12). The environmental influence may also lead to hyper methylation 
which can lead to silencing of tumor suppressor genes such as BRCA1/2 and TP53 (12;15). 
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1.2.4. Normal breast anatomy and breast cancer development 
Location of an adult female breast is between the second and sixth ribs, and it consists of skin, 
subcutaneous tissue and breast tissue. Each breast has 15-20 lobules surrounded by adipose 
tissue (Figure 4). The lobules produce milk, and the milk ducts carry milk from the lobules to 
the nipple. Blood supply is transported from internal mammary and lateral thoracic arteries. 
More than 95% of lymphatic drainage goes through the axillary lymph nodes (16). 
 
     
Figure 4. Anatomy of the breast. The figure shows the organization of the ducts and lobules with surrounding 
adipose tissue in the human breast. The cross section shows the lumen surrounded with luminal epithelial cells 
which are aligned in a polar manner. The myoepithelial cells surround the luminal epithelial cells in a non-
continuous layer. The basement membrane is surrounded by these cells and aligned by fibroblasts. The entire 
structure is surrounded by stroma (17). 
   
Atypical hyperplasia can either be atypical ductal hyperplasia (ADH) or atypical lobular 
hyperplasia (ALH). ADH is characterized by abnormal cells within the duct (Figure 5). ALH 
occurs in the epithelial cells lining of the milk lobules, which become irregular in size and 
shape. In in situ carcinomas, the tumor is still encapsulated by the basement membrane. The 
most common type is ductal carcinoma in situ (DCIS) and this cancer type are situated inside 
the milk duct (18). In the lobular carcinoma in situ (LCIS) abnormal cells are located in the 
lobules (19). In the invasive stage the degradation of the basement membrane has taken place, 
and the tumor cells invade the surrounding tissue (Figure 5). Invasive ductal carcinoma (IDC) 
means that the cancer is situated in the milk ducts. The cancer cells have broken through the 
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duct wall and have started to invade the surrounded tissue in the breast (20). Invasive lobular 
carcinoma (ILC) are located in in the milk-producing lobules and invades through the lobule 
wall and the breast tissue (21). Typical for ILC`s are small, round cells with less cytoplasm, 
which infiltrate the stroma without destroying it. ILC can have increased propensity for both 
bilateral disease, multifocal and multicentric distribution (22). Some of the tumor cells 
metastasize and migrate to different organs through blood and lymph vessels. 
 
Accumulation of acquired genetic alterations leads to tumor initiation and progression. 
Epigenetic and microenvironmental changes also play a role in this development (2;23). 
Epigenetic changes, such as DNA methylation, may lead to changes in the microenvironment. 
The microenvironment comprises of fibroblasts, myofibroblast, leukocytes, myoepithelial and 
epithelial cells among others. Studies have also shown that macrophages play a role in 
promoting angiogenesis, invasion and metastatic spread (23). 
            
       
 
Figure 5.  A hypothetic model of the breast cancer progression through the different stages in a duct of the 
breast. The figure of the normal breast duct illustrates an organized lining of epithelial cells surrounded by a 
basement membrane. The cancer development is illustrated through the hyperplasitic, in situ, invasive, and 
metastatic stage (24). 
 
The majority of the breast cancer cases (50-80%) are classified as invasive ductal carcinomas, 
Not Otherwise Specified (IDC NOS). The remaining ~25 % of cancer cases are defined as 
histologically “special types”, Weigelt and colleagues analyzed 11 of these by using 
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immunohistochemistry and genome-wide expression profiling (25). These special types are 
ILC, tubular, mucinous A, mucinous B, neuroendocrine, apocrine, IDC with osteoclastic giant 
cells, micropapillary, adenoid cystic, metaplastic and medullary carcinoma. Correct 
classifications of these special types can facilitate more optimal treatment and accurate the 
prognostic information for breast cancer patients. 
   
1.2.5. Breast cancer classifications 
Classification systems are useful tools for the clinicians when planning the treatment and 
estimating the prognosis of the patient. Different subtypes of breast cancer display differential 
aggressiveness and responses to the treatment. Some tumors are more malignant than others 
and require more aggressive treatment (26).  
      
1.2.5.1. Histological grades 
The grade refers as to how much the tumor cells resemble normal cells of the same tissue type 
(27). For breast cancer a modification of the Bloom-Richardson system is the most commonly 
used for the histological grading. The system is based on a description which combines 
architectural and nuclear characteristics of the tumor cells, and is based on a sum of the scores 
from of the following three parameters: tubule formation, nuclear pleomorphism and mitotic 
activity (Table 1) (16). The histological grades G1-G3 characterize the level of differentiation. 
Grade 1 is well differentiated and has a good prognosis, whereas Grade 3 is poorly 
differentiated with poor prognosis (28). 
 
Table 1. The histological grades for breast cancer. The sum of scores is based on tubule formation, nuclear 
pleomorphism and mitotic activity (16).   
  Histological grade     Sum of scores Characterization 
G1 3-5 Well differentiated 
G2 6-7 Moderately differentiated 
G3 8-9 Poor differentiated 
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1.2.5.2. Breast cancer stages 
The Tumor, Node, Metastasis (TNM) staging system was developed by The American Joint 
Committee on Cancer (AJCC). It is based on the tumor size (T), regional lymph node 
involvement (N) and whether the breast cancer has metastasized (M) or not (16;26;29). A 
combination of the different categories of T, N and M determines the stage of the breast 
cancer. Stage 0 describes non-invasive breast cancer and stage IV invasive metastatic breast 
cancer (Table 2).  
         
Table 2. A simplified table of the Tumor, Node, Metastasis (TNM) staging system.  
TNM system Category Short description 
T (Describes the primary tumor) Tx No classification due to missing 
information 
 T0 No primary tumor 
 Tis (DCIS or LCIS) Ductal or lobular carcinoma in 
situ 
                Tumor size: 
T1           =<2 cm            
T2           >2.0=<5.0 cm  
T3           >5 cm 
T4           Independent on size  
There are also subclasses within 
these categories.  
N (Describes whether or not the 
cancer has reached nearby lymph 
nodes) 
Nx No cancer detected or measured 
in nearby lymph nodes. 
 N0 Nearby lymph nodes do not 
contain any cancer. 
 N1, N2, N3 Number based on lymph node 
involvement and how much 
cancer is found in them. The 
greater the number the greater 
extent of the lymph node 
involvement. Also subclasses in 
these categories. 
M ( Describes whether or not the 
cancer has spread to other parts of 
the body) 
Mx Metastasis cannot be measured or 
found. 
 M0 There is no distant metastasis. 
 M1 Distant metastasis is present. 
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1.2.5.3. Hormone receptor status 
The level of the endocrine receptors is also important in describing the breast tumor. The 
endocrine receptors are estrogen receptor (ER) and progesterone receptor (PR). If the breast 
cancer cells are ER+, the growth will be promoted in by the presence of estrogen. PR+ tumors 
will grow in response to progesterone. The hormone receptor status is used to guide the 
treatment of the patient. Approximately 75% of the breast cancers are ER+ and the ER status 
can change over time. Of the ER positive cases 65% are positive for PR (30).  
1.2.5.4. The proliferation marker Ki67 
Ki67 is a protein marker which gives information about the proliferation rate of the cancer 
cells. The proliferation index is defined as the percentage of Ki67 positive cells. The 
proliferation rate describes how fast the cancer cells are growing and can be used as a 
measurement of aggressiveness.  
1.2.6. Molecular subtypes 
Breast cancer is a heterogenous disease. It is composed of a spectrum of different tumor 
subtypes with distinct cellular origins, etiologies and somatic changes (31). Gene expression 
profiling has contributed to a taxonomy called “intrinsic subtypes of breast cancer”. These 
subtypes are named basal-like, Her2-enriched, luminal B, luminal A and a normal breast like. 
These subtypes are correlated with patient outcome (32). A sixth subtype named “Claudin-
low” group was suggested as a subtype in 2007 and was further characterized in 2010 (33;34). 
The claudin-low subtype is similar to the mammary epithelial stem cell profile (34), and is 
ER, PR and human epidermal growth factor receptor 2 (HER2) negative. HER2 will be 
described more detailed in the subchapter 1.2.9. 
 
Curtis et al. (35) suggested ten groups based on an integrated genomic/transcriptomic study. 
This study describes how copy number alterations affect the gene expression and which novel 
subgroups should be the focus of further investigations (35). 
1.2.7. Treatment of breast cancer 
The classifications above are useful in determining which treatments the patients should 
receive. There are national guidelines for recommendations for surgery, radiotherapy and 
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systemic treatment. The treatment is multimodal (36) and may consist of surgery and different 
treatments such as chemotherapy, adjuvant hormonal therapy, immunotherapy, radiotherapy 
and targeted therapy. Some examples of targeted therapy of breast cancer are briefly 
described in the sub chapters below. 
1.2.8. Targeting estrogen receptor  
Tamoxifen (TAM) treatment is the usual endocrine therapy for (ER) positive breast cancer in 
pre-menopausal women. The pro-drug TAM is a non-steroid compound and has a competitive 
ER antagonist effect. Most of the metabolism of TAM occurs in the liver. The cytochrome  
p450 enzymes CYP3A4/5 and CYP2D6 metabolize TAM to the active metabolite Endoxifen 
(37). Norwegian Breast Cancer Group (NBCG) recommends that medicines which could 
inhibit CYP2DG activity should not been used in combination with TAM. Endocrine therapy 
can also give positive “side effect” on the skeletal on postmenopausal women (38). The drug 
has agonist activities in bone and liver. It mimics the effect of estrogen and prevents 
osteoporosis. 
  
Five years adjuvant treatment with TAM has increased the survival by 33 % during the first 
15 years after the start of the treatment (39). Recommendation for the treatment of 
postmenopausal women in Norway after surgery is two years with an aromatase inhibitor and 
a subsequent three years with TAM. Alternatively, aromatase inhibitor can be given for five 
years. An aromatase inhibitor stops the estrogen production in postmenopausal women 
resulting in less estrogen available for the stimulation of the ER receptor. The reason why 
premenopausal women are not treated with aromatase inhibitor is that the drug cannot stop the 
ovaries from producing estrogen. For premenopausal women the treatment is five years with 
adjuvant TAM treatment (40).  
 
1.2.9. Targeting human epidermal growth factor receptor 2 (HER2) 
Approximately 20-25% of the breast cancers have amplification and / or overexpression of the 
HER2/neu/ERBB-2 proto oncogene. This tumor type is related to worse outcome and higher 
recurrence rate compared to the HER2 negative breast cancer (41). Genetic alterations lead to 
overexpression and constitutive activation of the HER2 protein. In addition to HER2 also 
HER1, HER3 and HER4 exist and they are transmembrane tyrosine kinase receptors (42). 
Their oncogenic functions are among others stimulation of PI3K/AKT/mTOR signaling 
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pathway (43) followed by cellular proliferation and survival of cancer cells. PI3K/AKT 
signaling pathway and the PIK3CA gene are described more in detailed in the sub-chapters 
1.3.2 and 1.4.5. 
 
Trastuzumab (Herceptin) is a humanized murine monoclonal antibody. The antibody works as 
an antagonist and targets and blocks the HER2 receptor by binding to its extracellular domain 
(Figure 6). Inhibition of both growth and survival of cancer cells occur (42). Approximately 
30% of HER2 positive breast cancers respond to Trastuzumab treatment (44). Studies have 
been focusing on the mechanisms of resistance against this drug and the research is still 
ongoing in this field. A suggested biomarker for prognoses for this therapy is PTEN 
expression combined with PIK3CA mutation status (45). Loss of PTEN combined with 
mutations in PIK3CA in HER2 positive breast cancer predicts Trastuzumab resistance 
(43;44). 
 
Juntilla et al. (46) focused on activators in the PI3K pathway and Trastuzumab resistance. 
They found that combination of agents was more effective in preventing tumor growth than 
single agent. Breast cancer cells with loss of PTEN or activating mutations in the PI3K 
pathway show resistance to Trastuzumab but are sensitive to Lapatinib (44). Lapatinib is a 
tyrosine kinase inhibitor that inhibits the receptor signaling by binding to the ATP-binding 
pocket of the EGFR and HER2 protein kinase domains. Trastuzumab and Lapatinib act at 
different sites of the receptor. A combination of these two drugs may be beneficial. Trial are 
ongoing to evaluate Lapatinib in combination with endocrine or chemotherapeutic drugs and 
its role in an adjuvant setting (47).  Esteva et al. (48) found more Trastuzumab resistance and 
worse survival in HER2 positive breast cancer patients with loss of PTEN in combinations 
with multiple components altered in PI3K pathway. These selected studies illustrate the 
complexity of targeted therapy of HER2+ breast cancer tumors. Martini et al. (41) noted that 
integration studies on expression profile, copy-number alterations, and methylations together 
with the mutational status will refine the cancer picture. Then the predicted response to 
targeted therapies can be more precise.   
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Figure 6. Mechanism of Trastuzumab. The drug is a humanized murine monoclonal antibody and it acts as an 
antagonist by targeting and blocking the HER2 receptor. It binds to the extracellular juxtamembrane domain of 
the receptor (49).   
1.2.10. Integrating genomic levels in breast cancer  
In the last years the researchers have increased the focus on integrating at different –omics 
levels. An article from The Cancer Genome Atlas Network (TCGA) described analysis of 825 
primary breast cancer samples by combining data from five platforms, DNA methylation, 
exome sequencing,  DNA methylation, genomic DNA copy number arrays and exome 
sequencing (50). One of the findings was that the somatic mutation frequencies were more 
than 10% in only three genes across all breast cancers: TP53, PIK3CA and GATA3.  Ellis et 
al. summarized six recent integration studies including this article from TCGA. One of their 
conclusion marks was to identify driving genetic events together with the subtype of breast 
cancer. This is important for diagnosis and treatment purposes of this patient group (51). 
 
1.3. Signaling pathways 
Biological and physiological processes in a multicellular organism are coordinated and 
regulated by cell signaling. The cells cooperate by receiving and sending signals to each 
other. The environmental factor, such as temperature shock, nutrient molecules or differences 
in extracellular ion concentrations, can also influence the cells (52) .  
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The cell signaling regulates many processes such as differentiation, metabolism, proliferation 
and movement. Cell signaling is divided in three different types which are paracrine (between 
neighboring cells), synaptic (across the synaptic cleft) and juxtacrine (the transmitting cell and 
the responding cell are in directly contact) (52). The next subchapters focus on the p53 protein 
signaling pathway and the MDM2-p53 loop as a regulator for interactions within this pathway 
(53). The phosphatidylinositol 3-kinase (PI3K) signaling pathway is also presented. This 
pathway is the second most affected pathway with genetic aberrations after the p53 signaling 
pathway in cancer (44). More than 70 % of all breast cancers have mutations in genes 
involved in the PI3K pathway (54). PI3K and its downstream components show extensive 
cross-talking with several other signaling pathways. This leads to a complex network of 
signals (55). One of the main focuses is to understand the mechanisms in this network when 
developing combination therapies. The influence of activation of alternative cascades and 
feedback loops are also important to study (44).  
1.3.1. The p53 signaling pathway  
P53 protein is encoded by the TP53 tumor suppressor gene which has the highest mutation 
frequency with 31 % of all human tumors (7). Under normal conditions the p53 levels in the 
cells are low because p53 is destabilized mainly by the action of MDM2.  When the cells are 
affected by various types of stresses, p53 is released from MDM2 (Figure 7). Increased p53 
levels lead to various phenotypic changes and are partially dependent on the strength, duration 
and nature of the activating signal (53). P53 senses stress signals from oncogenes, DNA 
damage, telomere erosion or metabolic deprivation (7). The stress response can result in cell 
cycle arrest by inhibiting cell cycle progression, induction of apoptosis, DNA repair and 
metabolic homeostasis maintenance (56).  
 
MDM2 protein is an E3 ubiquitin ligase and also a Caspase 3 substrate. It regulates the p53 
expression and function (57).  MDM2 can bind to the transactivating domain of p53 and thus 
block the function of the protein. In addition, MDM2 can transport p53 from the nucleus into 
the proteasome for degradation (51). P53 is a tetrameric transcriptional factor. One of its 
targets is the MDM2 gene leading to increased MDM2 expression. The MDM2-p53 
autoregulatory feedback loop is the centrum of the p53 pathway. Another member of the 
MDM2 family is MDMX which also contributes to p53 degradation (53). 
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The crystal structure of the DNA binding domain (DBD) of the wild type p53 together with 
the target DNA is important for the understanding how the TP53 mutations affect the p53 
activity (7). Mutant p53 can also affect the micro-RNA expression (58;59), and after micro-
RNA processing the level in the cells have changed. In response to DNA damage, p53 
enhances the post transcriptional maturation of several micro RNA (miR-16-1, miR-143, 
miR-145, miR-34) with growth-suppressive function (58). Several studies have also 
implicated miR-34 family of miRNAs in the p53 network (60). P53 is a part of various 
physiological processes as fertility, cell metabolism and mitochondrial respiration, autophagy, 
cell adhesion, stem cell maintenance and development (3).  
 
 
 
Figure 7. A simplified scheme of the p53 pathway. Different stress signals lead to p53 release from MDM2, 
resulting in increased p53 levels. p53 effects transactivation of target genes, usually by repression. The stress 
response can be cell cycle arrest by inhibiting cell cycle progression, induction of apoptosis, DNA repair and 
metabolic homeostasis maintenance (53;56).  
 
1.3.2. The PI3K/AKT signaling pathway 
Normal tissues control the production of growth promoting signals and regulate the cell 
growth through regulation of the cell cycle. In cancer, this homeostasis is deregulated. In 
cancer cells the cell signaling is deregulated leading to abnormal activation of the pathway 
(5). The PI3K pathway is a part of this growth factor receptor (GFR) signaling and a key 
mediator for cell growth, proliferation and metabolism. Genomic alterations at different levels 
in the pathway lead to its abnormal activation and cancer development (44). 
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The PIK3CA proto-oncogene is encoding the catalytic subunit P110 α of PI3K and is the most 
frequently mutated gene (26% in COSMIC database) in breast cancer (7). 
Phosphatidylinositol 3-kinase (PI3K) superfamily has received considerable attention after the 
discovery that PI3K activity is associated with viral onco-proteins (44). Its role in prevention 
of apoptosis and growth regulation contribute to this focus. PI3Ks are grouped into three 
classes I, II, III. Class Ia PI3Ks comprises of PIK3Cα, PIK3Cβ, PIK3Cδ. They are proteins 
with regulatory subunit p85 and catalytic subunit p110 (44). The PIK3CA gene is encoding 
p110α subunit (61).  
 
The PI3K/AKT signaling pathway is triggered after growth factor activation of a receptor 
tyrosine kinase (RTK). Phosphatidylinositol is a phospholipid with an inositol head and it is a 
component of eukaryote cell membranes. The inositol head can be phosphorylated at multiple 
sites by phosphoinositide kinases (PIKs) (44). Adaptors, such as Gab2 or IRS family protein 
are then recruited. Gab2 or IRS family proteins bind to the regulatory p85 subunit of PI3K. 
Then the catalytic subunits p110α, β and δ are activated and the complex transformed to 
phosphorylate 4, 5-phosphoinositide (4, 5-PIP2) into second messenger 3,4,5-phospoinosite 
triphosphate (PIP3). PIP3 recruits proteins such as AKT and PDK1 to the plasma membrane. 
AKT is phosphorylated by PDK1 and PDK2.  Activation of AKT leads to modulation of 
different substrates (Figure 8) (62). AKT kinase is a nodal point in a complex network of 
signaling pathways. These substrates are important for survival, cell cycles and cell 
proliferation. 
 
PTEN and SHIP-1 are phosphatases and negative regulators of PI3K signaling by limiting the 
production of the second messenger PIP3. Up to 33% of all breast cancers have PTEN loss or 
decreased expression and this leads to tumor progression by activating of AKT /mTOR-
dependent cell proliferation (44).  
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Figure 8. A simplified scheme of the PI3K/AKT signaling pathway. The PI3K/AKT pathway is frequently 
activated in human cancer. After binding of a growth factor to the RTK, PI3Ks are recruited to the plasma 
membrane receptor where they phosphorylate PIP2 to generate PIP3. AKT kinase binds to PIP3 and becomes 
activated by phosphorylation. A cascade of signals occurs and leads to regulation of cell growth, protein 
synthesis, proliferation, survival and angiogenesis (63) .  
 
1.4. Cancer gene mutations  
1.4.1. Different types of mutations 
There is a lot of variation in DNA sequences in healthy human genomes. The sequences can 
be altered in different ways. Pathogenic DNA changes can lead to either disease or a 
susceptibility to diseases. These DNA changes occur in the regulatory region or in the coding 
part of a gene (52). There are also unknown numbers of functional elements in intronic and 
intergenic DNA (2). The somatic changes in cancer cells consist of different classes of DNA 
changes, like substitution of one base to another, small and large insertions and deletions of 
the DNA sequence, copy number increases and reductions, DNA rearrangements and 
epigenetic changes. Also somatic mutations in the mitochondria genome have been reported  
in different cancer cells (2).  
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1.4.2. Pathogenic DNA changes affecting one or few nucleotides 
A deletion is a removal of one or more nucleotides in the DNA whereas an insertion is 
addition of one or more nucleotides. Point mutation is an exchange of one nucleotide to 
another. A missense mutation which results in a codon change, leads to amino acid change in 
the protein. There are different types of substitutions. A conservative substitution means 
amino acid change within the same class (uncharged polar, uncharged non-polar, acidic, 
basic). This has less effect on the protein structure. The opposite situation is a non-
conservative substitution with amino acid changes between different classes and it has more 
effect on the protein structure.  Different codons can encode the same amino acid. A silent 
mutation is a nucleotide substitution in the codon without any amino acid changes in the 
protein. 
 
The genetic code comprises of 64 codons, of which three are stop codons. A nonsense 
mutation has occurred when a nucleotide substitution has led to a stop codon. A truncated 
protein can be more harmful than the absence of a protein because it can interfere with the 
function of the normal product (52). Nonsense –mediated decay (NMD) is a cellular 
mechanism which detects and degrades mRNAs containing premature terminations codons. It 
is a possible protection mechanism. The spliceosome recognizes the Guanine Thymine (GT) 
sequence as the beginning of all exons and Adenine Guanine (AG) sequence in the end of all 
exons in mRNAs. A splice site mutation in theses sequences can be an insertion, a deletion or 
a point mutation. The spliceosome will not recognize these sequences when they are changed 
and splicing will be disrupted. Silence and missense mutations can have a pathogenic effect 
on splicing (52). 
 
Variants such as small deletions and insertions within an exon, whole exon deletions, 
abnormal splicing and duplications can cause a frame shift. The reading frame starts with 
initiator codon Adenine Uracil Guanine (AUG). Downstream changes that add or remove a 
number of nucleotides not divided in three, will cause changes in the reading frame. When 3 
of 64 codons are stop codons and the reading is out of the frame, a stop codon will soon be 
reached (52).  
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1.4.3. Pathogenic DNA changes affecting many nucleotides in chromosomal 
structure 
The term amplification (copy number increase) is used when the genome has multiple copies 
of a chromosomal region. The genes dosage is increased and the consequence is larger 
amount of the gene product. The opposite term is deletion (copy number reduction). Large 
chromosomal regions are deleted and loss of genes within these regions occurs. A somatic 
genetic change such as deletion may cause a loss of heterozygosity. It means loss of one 
allele.   
1.4.4. Driver and passenger mutations  
Somatic mutations in a cancer cell genome are suggested to be classified according to its 
consequences for the cancer development. The first class called driver mutation consists of 
mutations which are able to favor and foster cells with proliferation and survival properties. 
The second class named passenger mutation is an individual genetic variation. One single cell 
needs a set of mutations to get the properties to proliferate autonomously and invade tissue 
and metastasize (2). Figure 9 describes the development of a cancer cell through the cell 
divisions from the fertilization to chemotherapy resistance at the recurrence phase.  
 
Driver mutations are in cancer genes and the number of driver mutations varies between the 
cancer types. Driver mutations will cause a clonal expansion. They are positively selected in 
the tissue microenvironment from which the cancer developed and they contribute to the 
oncogenesis (2). 
 
Cells with passenger mutations do not have growth advantage, thus they will not contribute to 
the tumor development. These mutations are more or less randomly distributed (2). 
McFarland and colleagues investigated the impact of deleterious passenger mutations on 
cancer progression  (64) . Many passengers fall within protein coding genes and can have 
deleterious effect on cancer cells. They have used a stochastic model to analyze cancer 
genomics data (from COSMIC and TCGA database) and two strategies were followed. First, 
they increased the overall mutation rate and thus increased the rate of passenger 
accumulation. In addition they magnified the deleterious effect of passengers. Both strategies 
reduced the cancer size. They also focused on passenger-mediated therapies (64). 
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A meta study of Stephens et al. (65) focused on driver mutations and mutational processes in 
100 breast cancer tumors. They studied mutations in exons of protein coding genes and 
somatic copy number changes. The number of somatic mutations varies markedly between the 
tumors. The number of driver mutations in the individual cancer varied from maximum six to 
a single driver. Somatic driver substitutions and small insertion/deletions were found in the 
following genes: AKT1, BRCA1, CDH1, GATA3, PIK3CA, PTEN, RB1 and TP53. These 
genes have earlier been described to be involved in breast cancer development. Stephens et al. 
conclude that driver mutations are operative in many cancer genes. In some cases, genes with 
driver mutations are associated with sub-clonal evolution, but in others in the root cancer 
clone (65). 
  
Stratton et al. (2) emphasized the importance to identify rare sub clones with drug resistance 
mutations before the cancer therapy is chosen. It is a challenge to distinguish clusters of driver 
mutations from random passenger mutations. This is dependent on driver mutation frequency 
and the prevalence of passenger mutations (2;66). Targeted therapy on the most common 
driver which is dominant and has expanded will not succeed if the cells have become 
resistant. Combined treatment are then feasible.  
 
 
 
Figure 9. Development from the fertilized egg to a single cell within a cancer by mitotic cell divisions. The 
illustration also shows the timing of somatic mutations acquired by the cancer cell and contribution of other 
processes (2).  
 
Stephens et al. (65) found that seven out of 40 genes (TP53, PIK3CA, ERBB2, MYC, 
FGFR1/ZNF703, GATA3, CCND1) were mutated in more than 10% of the 100 breast cancers. 
The PIK3CA and the TP53 genes are the two most frequently altered genes in human cancer. 
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Reasonable statistic indicates that they are likely to be driver genes (67). The PIK3CA and 
TP53 mutations will be discussed in more detail in the two following chapters.  
1.4.5. Mutations in the PIK3CA gene  
PIK3CA gene has hotspots (mutated codon in the gene) in exon 9 (helical domain) and exon 
20 (kinase domain) (Figure 10) (68). There is also a third hotspot in exon 7 (C2 domain). Saal 
et al. (69) found mutations in seven primary breast tumor of a total number of 292 (2,4 %) in 
hotspot 7. Samuels et al. (70) reported that mutations generally arise late in PIK3CA in the 
tumor development.  
 
 
 
Figure 10. Distribution of nonsynonymous (alter the amino acid sequence of a protein) mutations in the 
PIK3CA gene (61).  P110α gene product of PIK3CA is a catalytic subunit of phosphatidylinositol 3-kinase 
(PI3K). It consists of 5 domains: ABD, Ras-binding domain (RBD), C2 domain, helical domain and kinase 
catalytic domain (modified from Cheung et al. (61).  
 
1.4.6. Mutations in the TP53 gene 
The TP53 gene consists of different domains where all have been shown to contain missense 
mutations at different frequencies (Figure 11) (7). The Li- fraumeni syndrome is associated 
with germline mutations in the TP53 gene (16). Occurrence of different hotspot mutations in 
TP53 varies between the different tumor types, grade and survival of breast cancer (7). 
Mutation rates between the breast cancer subtypes vary between 5-95 % (71). The basal-like 
and HER2-enriched subtypes have the highest frequency of TP53 mutations and they are 
associated with poor prognosis. Also TP53 mutation types may differ between breast cancer 
subtypes. For example basal-like and BRCA1-mutated breast cancer has a high incidence of 
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protein-truncating mutations. This supports the fact that TP53 mutations have diverse effects 
in different cells of origin and conditions of cancer development (71).  
 
 
 
Figure 11. Frequency of p53 missense alterations in breast cancer.  “Human p53 domain structure with 
indicated frequency (percent bars) of missense changes in TP53 found in spontaneous (above) or Li-Fraumeni-
associated (below) breast cancer. The five most frequently changed codons are indicated by numbers and residue 
names”. (modified from Walerych et al. (7). 
 
1.4.7. Experimental targeting of p53 
Tumor cells do often overexpress mutant p53 which leads to reduced sensitivity to 
conventional chemotherapy and radiotherapy (72). Activation of mutant p53 by small drug 
molecules appears to be a greater challenge than for the wild type p53. One reason is that a 
large range of different mutant proteins expressed in the tumor might lead to different 
structural alterations. P53 is normally expressed at low levels but accumulate upon stress such 
as DNA damage. Targeting p53 leads to tumor suppression. A major concern of activating 
p53 are toxic side effects on normal tissues and cells (72). 
  
P53 is a transcriptional factor and not an enzyme and it has complicated protein-protein 
interactions (53). These challenges have to be overcome in developing targeted drugs. P53 
therapeutics has been tested in xenograft models (immunosuppressed mouse with a primary 
tumor implant) by interrupting the p53 and MDM2 interaction.  P53 can then be activated or 
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stabilized and tumor regression occurs. One class of p53 targeted drugs is the imidazoline 
derivatives called Nutlins. They interact with p53-binding pocket of the MDM2 molecule and 
dissociate p53 from MDM2 (53). An activation of p53 will then leads to induction of 
apoptosis. MDM2 inhibition can be a promising treatment strategy for Luminal B disease 
with wild-type TP53 (51). There is still a lack of knowledge on whether such small molecules 
affect healthy cells and tissue. PRIMA-1 and MIRA-1 are two small molecules which target 
cells that express mutant p53 and thus initiate apoptosis. More studies have to be done before 
testing these drugs in clinical trials (72). 
 
1.5. Ba/F3 as a model system 
It is important to study the effect of different mutations in order to understand therapy 
resistance and to develop better treatment strategies. For that purpose, researchers have 
developed cell line model systems, such as the Ba/F3 model. The Ba/F3 cells were first 
characterized by Palacios and Steinmetz who isolated IL-3 dependent pro-B cells from bone 
marrow of normal and autoimmune-prone BALB/c mice (73). These clones carried B cell 
lineage surface antigen B-220. They died within 24-36 hours in the absence of IL-3 and the 
mean doubling time was about 14-18 hours in a logarithmic growth phase. Daley and 
Baltimore (74) did the first landmark experiment and launched the use of Ba/F3 cells by 
infection of the Ba/F3 cells with retroviral constructs encoding the protein derived from the 
hybrid gene created by the Philadelphia chromosome  (P210 
bcr/abl
 ). Cell lines expressing 
P210 
bcr/abl
 were IL-3 independent and tumorigenic in nude mice. Since then the Ba/F3 cells 
have been used as a tool in cancer research (75). 
 
The Ba/F3 cells have many properties which can be exploited in a model system. These cells 
are fast growing suspension cells with a rapid experimental turnaround. Both virus 
transduction and electroporation have been used for transfection of the Ba/F3 cells. The Ba/F3 
cell line with active tyrosine kinase or other oncogene has the possibility to survive in the 
absence of IL-3 (75).  Protein kinases are able to function as dominant oncogenes. Following 
are some examples of how Ba/F3 cells have been applied in kinase drug discovery. 
Transfected Ba/F3 cells can be used when characterizing whether they express oncogenic 
mutations i.e. have testing the transforming potential or not. It is also possible to study 
downstream signaling mechanisms of mutant kinases. Warmuth et al. (75) summarizes the 
use of Ba/F3 model system to investigate mutants in the Janus kinases Jak 2 and Jak3. 
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Research groups have found that mutants in genes encoding these kinases have potential to 
function as oncogenes in hematopoietic malignancies (76;77). Walters et al. found different 
regulations of JH1 domain through JH2 domain in these two kinases. The structural basis of 
this phenomenon has to be investigated by crystallographic studies. They also presented a 
study by using Ba/F3 cells to identify gain of function mutations in three types of Jak 3 
kinases. These findings are clinically important information in numerous malignancies such 
as acute myeloid leukemia (AML) (76).  
 
Ba/F3 model system is also used for testing the response of various drugs for oncogenic 
mutants. The effect of inhibition of cell growth by targeted drugs varies, and the 
consequences are growth arrest and apoptosis. The Ba/F3 cells will be rescued by adding IL-3 
to the growth medium when testing the drug. Then the number of viable cells will not 
decrease. This is used as a control to be compared with drug testing in growth media without 
IL-3. Because of the growth property of the Ba/F3 cells, this model system is suitable to be 
adapted to high throughput drug screening systems. Melnick et al. (78) describes a robotic 
system for testing a panel of 35 activated tyrosine-kinase dependent cellular assays in dose –
response format against a set of 1400 kinase inhibitors in a single experiment. 
  
It is important to predict mutations that cause resistance to a drug. The Ba/F3 model system 
gives the possibility to screen for mutations inducing treatment resistance. The system has 
also limitations and one example is that other several distinct resistance mechanisms can be 
involved. It is difficult to separate between these mechanisms. Bradeen et al. (79) have 
developed a rapid mutagenesis assay to avoid these limitations. Their protocol is based on a 
chemical mutagenization of Bcr-Abl cDNA with N-ethyl-N-nitrosourea (ENU), which is a 
potent inducer of random point mutations. Then the mutant gene is introduced into Ba/F3 
cells. This assay was used to test for resistance profile of four drugs alone and in 
combinations.  
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2. Material and methods 
The names of the reagents and equipment together with catalog numbers, manufactures and 
suppliers used are listed in the Appendix A.  
2.1. Cell line and plasmids 
The detailed information about the Ba/F3 cells and plasmids used in this study are listed in 
Table 3. Plasmid TP53 wild type (wt) and PIK3CA wt contained both Blasticidin- and 
Ampicillin resistance genes and were used as DNA templates in the mutagenesis and also as 
controls for normal transfection and viability.  Figure 12 shows the map of the plasmid 
vectors for the human TP53 wt coding sequence and the vector pLenti 6.3 for the human 
PIK3CA wt coding sequence.   
       
Table 3. Overview of cell line and plasmids. 
Cell lines and 
plasmids 
Description Supplier 
Ba/F3 cell line Ba/F3 is a murine, interleukin-3 (IL-3) –dependent pro 
lymphoid cell line (75).  
Gordon Mills 
laboratory, Houston, 
Texas, USA 
Plasmid PIK3CA WT Plasmid background was Plenti 6.3 (10,8 kilobase (kb). 
PIK3CA coding sequence was 3,3 kb and total size was 14,1 
kb. The plasmid contained both Blasticidin- and Ampicillin 
resistant genes. 
Gordon Mills 
laboratory, Houston, 
Texas, USA 
Plasmid TP53 WT Human cDNA SC119832 (80) TP53 coding sequence with 
accession no: NM_000546.2 (1,2 kb) was sub cloned into 
the vector pCMV6-A-BSD (PS100022) (81) (5.5 kb). The 
total size was 6,7 kb. The plasmid contained both 
Blasticidin- and Ampicillin resistant genes.  
OriGene 
Technologies Inc., 
USA 
Plasmid PIK3CA, 
E545K 
Plasmid  background was Plenti 6.3 (82)  (10,8 kb) and 
contained both Blasticidin and Ampicillin resistant genes. 
Gordon Mills 
laboratory, Houston, 
Texas, USA 
Plasmid LacZ Plasmid background was Plenti 6.3.  Gordon Mills 
laboratory, Houston, 
Texas, USA 
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Figure 12. The map of the plasmid vectors (83;84). a) Human TP53 wt coding sequence was sub-cloned into 
pCMV6-A-BSD vector by Origene. b) Human PIK3CA wt coding sequence was sub-cloned into pLenti6.3/V5-
DEST vector by M.D. Andersson. The plasmids were both Blasticidin (BSD) - and Ampicillin (Amp
r
) resistant.  
2.2. Cell culturing 
Cell culturing was performed in sterile condition in laminar flow hood (LFH). 75% ethanol 
(Antibac AS, Norway) was used for disinfection. The cells were cultured in a Corning petri 
dish, 100 x20 mm (Corning Incorporated, NY USA) in a CO2 incubator (Nerliens Meszansky, 
Norway) at 37 
○
C with 5 % CO2.   RPMI 1640 with L-Glutamine (Gibco
®
, USA), 5 % fetal 
bovine serum (FBS) (Gibco
®
) and Recombinant Mouse Interleukin-3 (IL-3) 5 ng/ml (Gibco
®
) 
was used for the parental Ba/F3 cells. Blasticidin S HCL (Invitrogen, USA) was used as a 
selection antibiotics for the transfected Ba/F3 cells. 
  
The Ba/F3 cells were stored in -170 
○
C in liquid N2 tank (Taylor-Warton, Germany) with 10 
% Dimethyl Sulfoxide (DMSO) (Thermo Scientific,USA) and 90 % FBS (Gibco
®
). The cells 
were cultured for 14 days and the confluence level was approximately 80 % before starting 
the experiments. The Ba/F3 cells are suspension cells and were split by transferring cell 
suspension directly to a new dish containing fresh media. The split ratio for the parental 
Ba/F3 cell line was 1/10. When performing new experiments the cell suspension was 
centrifuged (Hettich Rotina 420, Germany) at 1000 rotation per minutes (rpm) for 5 minutes, 
the supernatant was removed and the cell pellet was resuspended and diluted in fresh Ba/F3 
medium.   
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2.3. Mycoplasma detection 
Mycoplasma is a small prokaryote organism < 1 µm. It competes with the cultured cells by 
using nutrients in the medium. Supernatant of cultured Ba/F3 cells was tested for mycoplasma 
contamination. The mycoplasma test was performed by using MycoAlert
R
 Mycoplasma 
Detection kit (Lonza Nottingham, UK) which contained both MycoAlert
R
 Reagent and 
Substrate. It is based on a bioluminescent reaction as described in Figure 13. 
 
 
Figure 13. The Luciferase reaction. Beetle Luciferin changes to Oxyluciferin and the reaction is catalyzed by 
Luciferase, Mg2+, ATP and O2. The luminescence signal is proportional to the presence of ATP which reflects 
viable cells in the culture (85). 
  
The MycoAlert
R
 Reagent was added to the cell culture supernatant at room temperature to 
lyse the mycoplasma. The background luminescence was measured before adding the 
MycoAlert
R 
substrate. If the cell culture contains mycoplasma, released enzymes from lysed 
mycoplasma react with the substrate catalyzing the conversion from ADP to ATP. The 
luciferase reaction is catalyzed by ATP, O2, Mg
2+
 and Luciferase. The intensity of emitted 
light is proportional to the ATP concentrations and was measured using Promega Glomax 96 
microplate Luminometer (Promega, USA). Duplicates from cell supernatant from early 
passage were measured (86). 
 
2.4. Cell counting 
The cell number was determined by counting using a Bürker chamber (Assistant, Germany). 
The cell suspension was diluted 1/2 with Trypan blue (Invitrogen, USA) and 10 µl of the 
colored cell suspension was transferred to the chamber. Separation between blue dead cells 
and bright living cells was easier by using this color method. Cells were counted in five of 16 
sub chambers as shown in Figure 14. The average number of living cells was calculated by 
the following formula: 
Cell number average x dilution factor x 10000 = number of cells/milliliter (ml). 
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Figure 14. Bürker cell counting chamber. a) Five of 16 sub chambers were counted, marked by arrows. b) The 
black spots represent cells which were counted. The white spots represents cells which were touching two out of 
the four edges and were not counted (87).   
 
2.5. Cell viability assay 
The detection method of viable cells in the culture was the Cell titer Glo
R
 (CTG) luminescent 
cell viability assay (Promega). It is based on the Luciferase reaction as described in Figure 13. 
20 µl CTG reagent was added to the wells and thus lysed the cells. After incubation with CTG 
reagent for 35 minutes in dark at room temperature, the luminescence signals were measured 
on a Wallac 1450 Micro Beta TriLux luminescence Counter (PerkinElmer, USA) with the 
MicroBeta Windows Workstation (PerkinElmer).  
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2.6. In vitro site directed mutagenesis 
2.6.1. Primer design for mutagenesis 
The Ensemble Genome Browser (88) was used to get the sequence information for the genes 
of interest. The Clustal Omega software (89) was used for alignment of TP53 reference 
sequences to the reference sequence in the Seqscape v.2.5 software. This was done to decide 
which transcript variant to choose for ordering of the custom made TP53 wt vector. 
Snipper.chip.org (90) was used to find where the mutation is located in the PIK3CA gene. The 
length of the primers was limited to 45 bp, as a longer primer could affect the mutagenesis 
efficiency due to likelihood of secondary structure formation (91). The primer design program 
which was used is from Stratagene, USA. It is designed for the QuickChange II XL site-
directed mutagenesis kit (Stratagene) (92). The sequences of the mutagenesis primers with the 
introduced mutations are shown in Table 4. 
 
Table 4. Mutagenesis primers.
Primer name 
Length 
(nucleotide) 
Melting 
temperature 
(Tm) 
Primer Sequence (5`to 3`) 
PIK3CA S405F sense 37 78.28 
°
C 5`-ctgctcgactttgccttttcatttgctctgttaaagg-3` 
PIK3CA S405F 
antisense 
37 78.28 
°
C 5`-cctttaacagagcaaatgaaaaggcaaagtcgagcag-3` 
TP53 K120E sense 33 80.38 
°
C 5`-gcattctgggacagccgagtctgtgacttgcac-3` 
TP53 K120E antisense 33 80.38 
°
C 5`-gtgcaagtcacagactcggctgtcccagaatgc-3` 
TP53 H179R sense 25 80.02 
°
C 5`-gctgcccccaccgtgagcgctgctc-3` 
TP53 H179R 
antisense 
25 80.02 
°
C 5`-gagcagcgctcacggtgggggcagc-3` 
 
 32 
 
2.6.2. Site directed mutagenesis 
In vitro Site-directed mutagenesis is a method used to create plasmids containing a mutant 
gene. In this study we created plasmids with mutated PIK3CA and TP53 genes (Figure 15). 
 
 
 
Figure 15.  In vitro site-directed mutagenesis. a) Mutant strand synthesis after denaturation by thermal cycling. 
b) digestion of parental methylated and hemi methylated  DNA with Dpn1. The mutant molecules were then 
transformed into competent cells for nick repair (93). 
 
The mutagenesis was performed by using Quickchange 
R
II XL site-directed mutagenesis kit. 
Control and the sample reactions were pipetted and run on the PCR machine as described in 
Table 5, 6 and 7 (93). The water used in the PCR reactions was Distilled Water, 
DNase/RNase Free (Gibco
®
).  
 
Table 5. Control reaction.  Pipetting scheme.  
Reagent Volume for each tube (µl) 
10 X reaction buffer 5 
pWhitescript 4.5-kb control plasmid (5 ng/µl) 2 
Oligonucleotide control primer # 1 (100 ng/µl) 1.25 
Oligonucleotide control primer# 2 (100 ng/µl) 1.25 
dNTP mix 1 
Quick solution reagents 3 
Distilled Water, DNase/RNase Free 36.5 
PfuUltra HF DNA polymerase (2.5 U/µl) 1 
Total volume of control reaction 51 
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Table 6. Sample reaction.  Pipetting scheme. 
Reagent Volume for each tube (µl) 
10 X reaction buffer 5 
dsDNA template (5 ng/µl) 2 
Oligonucleotide sense primer (100 ng/µl) 1.25 
Oligonucleotide antisense primer(100 ng/µl) 1.25 
dNTP mix 1 
Quick solution reagents 3 
Nuclease free water 36.5 
PfuUltra HF DNA polymerase (2.5 U/µl) 1 
Total volume of sample reaction 51 
 
Table  7.  The PCR program for the mutagenesis. 
Cycles Temperature Time 
1 95
 
°C 1 minute (min) 
12
a
 
or 
18
b
 
95 °C 
60 °C 
68 °C 
50 seconds(sec) 
50 sec 
1 min/kb of plasmid length 
1 68 °C 5min
c
/ 7min
d
/12min
e
 
 4 °C ∞ 
a) 
for the pWhitescript control 
b) 
for the PIK3CA- and the TP53 wt plasmid
c) 
for the pWhitescript control 
d)
 for 
the TP53 wt plasmid
e)
 for the PIK3CA wt plasmid 
 
The PCR products were digested with Dpn I endonuclease at 37 
○
C for 1 hour to degrade the 
wt plasmid which is susceptible to degradation because it is methylated. The mutant plasmids 
were transformed into ultra-competent XL10 Gold E.coli cells for nick repair. The Hte 
phenotype which was representative in these bacteria increased the transformation efficiency 
of ligated DNA, and their content of lacI
QZ∆M15 gene permitted blue-white screening. These 
competent cells also contained end A1- and recA mutations which improved the quality of the 
plasmid  mini prep DNA and ensured insert stability (93). 45 µl of the competent cells were 
aliquoted into pre cooled tubes together with β-Mercaptoethanol, carefully mixed and 
incubated on ice for 10 min. 2 µl of sample plasmids, pWhitescript control and TP53 wt 
plasmid and 1 µl of the other controls were added in each tube of competent cells and 
incubated on ice for 30 minutes. Transformations were performed by a heat shock at 42 °C for 
30-40 seconds at a heating block before the tubes were transferred to ice for 2 minutes to stop 
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the reactions.  Pre-warmed Luria broth (LB) medium pH 7,0 was added to the reactions before 
incubation in 37 
○
C for 1 hour at 220 rpm. LB agar plates contained 0,05 mg/ml Ampicillin 
(Invitrogen, USA). The LB agar plates were added 100 µl of 10 mM Isopropyl-1-thio-β-D- 
galactopyranoside (IPTG) (Sigma-Aldrich, USA) and 110 µl of 50 µg/ml 5-bromo-4-chloro-
3-indolyl-β-D-galactopyranoside (X-gal) (Sigma-Aldrich). After the transformation, colonies 
can be screened for β-galactosidase production (β-gal+) by virtue of a blue colony phenotype 
(93). Whitescript control plasmid, pUC18 control plasmid (diluted 1/40 with LB medium) and 
sample plasmid were spread out on the LB agar surface and air dried. The plates were 
incubated at 37°C over night. 
 
2.7. Culturing of transformed bacteria, mini- and midi preparation of 
plasmid DNA 
2.7.1. Mini preparations 
Mini preparations were performed using with QIAprep
R
 spin mini prep kit (Qiagen,USA) (94) 
to isolate plasmid DNA in small scale in order to identify the clones that carried mutated 
plasmids. Ampicillin (0,1 mg/ml) was added to 5 ml pre warmed LB medium in falcon tubes 
(BD Biosciences, USA). Single bacterial clones from the LB plates were transferred to the 
falcon tubes and then spread out in separate sectors on a new LB plate for storage. The 
cultures were incubated by shaking at 200 rpm, 37 
○C ≥ 16 hours. The LB-plate with seeded 
bacteria in sectors was placed in an incubator at 37 
○C ≥ 16 hours before storing at 4 °C. After 
incubation the falcon tubes were centrifuged (Hettich Rotina 420, Germany) at 3000 rpm for 
10 minutes. The supernatants were removed and the mini prep protocol (94) was followed.  
 
2.7.2. Midi preparations  
Single transformated bacterial clones were picked and cultured for midi preparation to isolate 
a larger amount of plasmid DNAs. Each of the transfected bacterial clones picked from the 
LB plate, were transferred to separate Falcon tubes containing 5 ml LB medium and final 
Ampicillin concentration 0,1mg/ml. The tubes were incubated by shaking (New Brunswick 
Scientific E24, USA) at 200 rpm and 37 
○
C for approximate six hours. 1000 µl of each of the 
bacterial suspensions were added to sterile Falcon Erlenmeyer Culture flasks (BD 
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Biosciences, USA) containing 100 ml of LB medium and Ampicillin (0,1 mg/ml). The flasks 
were incubated over night at 37 °C 200 rpm. 
 
Next day, 100 µl of minimum 99 % sterile Glycerol (Sigma Aldrich, USA) and 500 µl of each 
bacterial suspension were mixed in 2 ml Cryo tubes (Greiner, Germany) to a final Glycerol 
concentration of ~17 % and frozen at -80
○
C for long time storage. The six different glycerol 
stocks have TP53 wt, PIK3CA wt, LacZ, TP53 H179R, TP53 K120E and PIK3CA S405F 
genes represented in the plasmids. The bacteria were pelleted by centrifugation at 4754 
relative centrifugal force (rcf) for 13 minutes. Thereafter the supernatants were removed and 
Cell Resuspension Solution from the midi prep kit PureYield
TM
 Plasmid Midi prep System 
(Promega) was added to the pellets and the kit protocol (95) was followed.  
 
2.8. DNA Sequencing  
2.8.1. Primer design for sequencing 
The sequencing primers were design with Primer3 program (91). 
 
Table 8. Sequencing primers.
primer name Length 
(nucleotide) 
Tm  Primer Sequence (5`to 3`) 
PIK3CA ex6FM13BAF 
sense 
20 58.84 °C 5`-tgtaaaacgacggccagtaccttgttccaatcccaggt-3` 
PIK3CA ex8RM13BAF 
antisense 
20 58.29 °C 5`-caggaaacagctatgacctggccaaagattcaaagcca-3` 
TP53 ex4FM13BAF sense 20 58.47 °C 5`-tgtaaaacgacggccagttgtcccttcccagaaaacct-3` 
TP53 ex6RM13BAF 
antisense 
20 58.94 °C 5`-caggaaacagctatgaccataagatgctgaggaggggc -3` 
 
2.8.2. Sequencing and data analysis 
The validation of the site-directed mutagenesis was performed by the BigDye
R
Direct 
Sequencing Kit (Applied Biosystem, USA) on the Applied Biosystems 3730 DNA analyzer 
(Applied Biosystems) (96). Sequencing Analysis software v. 5.2 (Applied Biosystems) was 
used for data analyzes. The workflow of the sequencing method is shown in Figure 16. 
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Figure 16. Workflow of the sequencing method. 
 
The sequences of the PCR primers are described in Table 8 and the PCR reactions were 
prepared as described in Table 9. A negative control without any DNA template was included 
in the analyses. 
 
Table 9. Pipetting scheme for the PCR reaction in one well. 
Reagent Volume for each well (µl) 
Mutant Plasmid DNA (5 ng/ul) 1 
M13 universal sense primer (0,8 µM) 0.75 
M13 universal antisense primer (0,8 µM) 0.75 
BigDye
R
 direct PCR Mastermix 5 
Nuclease free water 2.5 
Total volume of each reaction 10 
 
 
The PCR amplifications were run with DNA Engine tetrad 2 Peltier Thermal Cycler (Bio-Rad 
laboratories, USA). The PCR amplification conditions are listed in Table 10. 
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Table 10. Time and temperature conditions of PCR amplification. 
Cycles Temperature Time 
1 96 C
○
 5 min 
35 94 C
○
 
59 C
○
 
68 C
○
 
30 sec 
45 sec 
45 sec 
1 72 C
○
 2 min 
1 4 C
○
 ∞ 
 
2 µl of each of the PCR products were mixed with 2 µl gel loading buffer and applied on an 
1.5 % agarose gel contained GelRed
TM
 nucleic Acid Gel Stain (Biotium, USA). 2µl DNA 
ladder øx 174-Hae III digest (TaKaRa, Japan) was used in a separate well. The gel was run for 
30 minutes at 200 Voltage (V) and the GeneGenius Bio Imaging System (Syngene, UK) was 
used for visualization. The sequencing reactions for each sample were prepared as described 
in Table 11 and 3 µl sequencing reaction mix was added to each samples. 
 
Table 11. Pipetting scheme for the sequence reaction in one well.  
Reagent Volume for each well (ul) 
BigDye Direct Sequencing Master Mix 2 
One sequencing primer: 
BigDye
R
 Direct M13 sense primer or  
BigDye
R
 Direct M13 antisense primer 
1 
Total volume of sequencing reaction mix 3 
                      
The sequence reactions were run on the DNA Engine tetrad 2 Peltier Thermal Cycler and the 
sequence reaction conditions are displayed in Table 12. 
 
Table 12. Time and temperature conditions during cycle sequencing.  
Cycles Temperature Time 
1 37 C
○
 15 min 
1 80 C
○
 2 min 
1 96 C
○
 1 min 
25 96 C
○ 
50 C
○ 
60 C
○
 
10 sec 
5 sec 
4 min 
1 4 C
○
 ∞ 
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Purification of the sequencing product was performed by using BigDye
R
XTerminator
TM
 
Purification Kit (Applied Biosystems) (97). 45 µl SAM
TM
 and 10 µl Xterminator
TM  
solution 
were added to each sample. The sample mix was added on the 96 well plate, sealed, vortexed 
and centrifuged. All empty wells were filled with nuclease free water before starting of the 
capillary electrophoreses. The 96 well plate was sealed with septa (Applied Biosystems) 
before sequencing on the 3730 DNA analyser. The principle of the Applied Biosystems 3730 
DNA analyzer is: fluorescent labelled DNA fragments are separated according to molecular 
weight in a denaturing flowable polymer (98). Negatively charged DNA molecules from the 
buffered cycle sequencing reaction enter the capillary by an electro kinetic injection. Before 
reaching the positive electrode the fluorescence labelled DNA fragments move across the path 
of a laser beam and start to fluoresce. An optical detection in the instrument detects the 
fluorescence and converts it to digital data by data collection software. In one capillary 
injection all four bases can be detected and distinguished. Each dye emits light with different 
wavelength and all four colours represent all four bases. The sequencing results were analysed 
and reviewed by sequencing Analysis software v. 5.2 (Applied Biosystems). 
 
2.9. Transfection of Ba/F3 cells  
Before the transfection of Ba/F3 cells, the plasmid DNA was concentrated by a speedvac 
procedure (DNA120 SpeedVac
®
 ThermoSavant (Houm, Norway) to get a final concentration 
of 1 µg/µl. One million parental Ba/F3 cells were used for each transfection. The cells were 
washed with Phosphate buffered saline (PBS) (GIBCO
®
) and resuspended in 80 µl 
Resuspendation buffer (R). Then 30 µl of plasmid DNAs with concentration 1 µg/µl were 
transferred to the sample tubes. The pulse conditions during the transfections on the Neon 
Device (Figure 17) were one pulse with 1635 Voltage for 20 milliseconds (protocol from MD 
Andersson). The Electrolytic buffer (E2) was added to the Neon
TM
 Tube before the sample 
was pipetted by the Neon
TM 
pipette and inserted in to the pipetting station. After the 
electroporation the transfected Ba/F3 cells were transferred to six-well plate containing Ba/F3 
medium with IL-3. PIK3CA S405F, TP53 K120E and TP53 H179R were the sample plasmids 
that were transfected. The control samples were Mock, parental Ba/F3, PIK3CA P110 wt, 
PIK3CA P110 E545K, LacZ and TP53 wt. These controls were used in order to be able to 
compare growth rate of the cell cultures and the transfections. 
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Three days after the transfections the selection with Blasticidin (Invitrogen) was started. The 
final concentration of Blasticidin in the cell cultures were 20 µg/ml. After maintenance and 
Blasticidin selection for a ten days period, the cell cultures were transferred to a 48 well plate 
and cultured with Ba/F3 medium without IL-3. The transfected cell cultures were evaluated 
microscopically and photographed. Ampoules of transfected samples PIK3CA P110 S405F, 
TP53 H179R and PIK3CA P110 E545K were mixed with DMSO and stored in the liquid 
Nitrogen tank to have a backup stock. The cell viability was confirmed by Trypan blue 
staining and CTG assay. 
 
 
      
Figure 17. Neon
TM 
transfection System. The bench top device was used together with a pipette station, a tube, 
pipette tips, pipette and 100 µl Neon™ kit (99). 
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3. Results 
3.1. Mycoplasma testing of the parental Ba/F3 cell line   
The parental Ba/F3 cell culture was examined for Mycoplasma infection. A Mycoplasma 
contamination may lead to reduction in proliferation rate of the cells. The reason for this is a 
competition between the cells and the Mycoplasma for using nutrients in the culturing media. 
MycoAlert
R
 reagent was added to two duplicates of supernatant of parental Ba/F3 cells. The 
luminescence values were read before and after the addition of the substrate. Possible 
mycoplasma enzymes react with the substrate and catalyze the reaction of ADP to ATP. The 
luminescence signal is proportional to the presence of ATP that reflects the activity of any 
mycoplasma enzymes. If the ratio of the second luminescence value against the first 
luminescence value is below one there is no mycoplasma in the culture. The result from the 
mycoplasma test (Table 13) show that the Ba/F3 cells were free from mycoplasma 
contamination as the luminescence ratio was below one. 
 
Table 13. Results of the mycoplasma test on the parental Ba/F3 cell line. The column with the luminescence 
ratio shows the results of two duplicates of supernatant of the cell culture. The ratios were below one and the cell 
culture was not infected by mycoplasma. 
 Run number        Luminescence ratio 
1 0.30 
2 0.31 
 
3.2. Optimization of the cell number of Ba/F3 cell line on 384-well plate 
The purpose of this experiment was to find the optimal number of parental Ba/F3 cells for 384 
well plate after three days culturing. The total volume of cell suspension was 50 µl in each 
well in a 384 well plate. The optimal number of parental Ba/F3 cells in a 384 well plate was 
going to be used for optimization of the Blasticidin concentration, and also for testing of 
parental Ba/F3 cell growth in media with- and without IL-3 in the same plate format. 
 
Six different dilutions of cell suspensions were made: 500, 800, 1100, 1400, 1700 and 2000 
cells/50 µl. Eight replicas of each dilution were added in one row in the 384 well plate. After 
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72 hours incubation the cell viability was assayed with CTG. The results are shown in Figure 
18. The optimal parental cell number selected to use for further analyzes is 700 / well in a 50 
µl total volume. The growth curve shows uniformly increased in the exponential phase, and 
the middle part of that phase was selected for the optimal cell number. In addition, the cells 
were evaluated visually in the microscope. 
 
 
 
Figure 18. Growth curve of parental Ba/F3 cells. The X-axis represents the number of cells/50 µl total volume 
and the Y-axis illustrates the luminescence values. Each data point represents the average value of eight 
replicates. 
 
3.3. Optimization of Blasticidin concentration 
Blasticidin was used as a selection marker for transfected Ba/F3 cells. The goal for this 
optimization was to find the lowest concentration of Blasticidin needed for the parental cells 
to die. The parental Ba/F3 cells are not Blasticidin resistant. 700 parental cells were added in 
384 well plate and Blasticidin was added to a final concentrations: 10, 15, 20, 25 µg/ml. Five 
replicates of each cell suspension with different Blasticidin concentration was pipetted on to 
the 384 well plate. One row with 5 replicas of parental cells without Blasticidin, and one row 
with five replicas with only media were used as controls in the experiment. After three days 
culturing the cell viability was measured with CTG. Optimal Blasticidin concentration used 
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for selection of transfected Ba/F3 cells is 20 µg/ml (Figure 19). The experiment was 
performed twice. 
 
 
 
 
Figure 19. Optimization of Blasticidin concentration for Ba/F3 cells. The X-axis represents different 
Blasticidin concentrations and the Y-axis illustrates the luminescence values. Each data point represents the 
average value of five replicates.   
3.4. Testing of cell growth of parental Ba/F3 with and without IL3 in the 
culture medium 
Ba/F3 cells are IL-3 dependent (75). To confirm this we made dilutions of 700 cells / 50 µl 
total volume with five replicates, with IL-3 and without IL-3 in a 384 well plate. After three 
days culturing the cell suspensions were stained with Trypan blue and cell viability measured 
with CTG. The results in Figure 20 image a) show no living cells in media without IL-3, but 
only precipitations from the staining solution. Image b) shows bright spots with viable Ba/F3 
cells in media with IL-3. Image c) and d) are from the 384 plate wells before the CTG reagent 
was added. Image number c) is cell suspension without IL-3 and shows no living cells. Image 
number d) is cell suspension with IL-3 and there are many viable cells growing in clusters.  
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Figure 20. Images of Bürker chambers and wells in a 384 well plate. a) Bürker chamber with no living cells 
in medium without IL-3, only precipitations from the staining solution. b) Bürker chamber with bright spots 
represented viable Ba/F3 cells in medium with IL-3. c) cell suspension in a 384 well with medium without IL-3 
with no living cells. d) cell suspension in a 384 well with medium with IL-3 with many living cells growing in 
clusters. (10x) magnification.      
 
The cell viability assay was performed and the results are shown in Figure 21. The average 
and standard deviation of the luminescence values of five replicates with and without IL-3 in 
the media are represented by the columns. There is higher luminescence value with IL-3 and 
no signal without IL-3. The differences in the pictures 20 a-d and the luminescence numbers 
confirm that the parental Ba/F3 cells are IL-3 dependent. 
 
a) b) 
c) d) 
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Figure 21. Cell viability assay to confirm the IL-3 dependency of Ba/F3.  These average luminescence 
numbers of five replicates confirmed parental Ba/F3 cells dependency of IL-3 in the culturing media.   
3.5. In vitro site directed mutagenesis 
In order to get plasmids containing the mutants we performed site directed mutagenesis. After 
mutagenesis, three - six clones of transformed bacteria with plasmids PIK3CA P110 S405F, 
TP53 K120E and TP53 H179R were picked for mini preparations. DNAs were isolated and 
Tables 14 and 15 show high concentrations, amounts and good quality of DNA. Only 10 ng 
DNA is needed for confirmation of the results by DNA sequencing. 
 
Table 14.  Nanodrop results of PIK3CA P110 S405F plasmid mini preparations. 
Sample parallel DNA concentration 
(C) µg/ml 
260/280 
ratio 
Total amount of DNA (µg) 
1.1 (PIK3CA  P110 S405F) 169,04 1.86 8,45 
1.2 (PIK3CA  P110 S405F) 88,28 1.85 4,41 
1.3 (PIK3CA  P110 S405F) 114,27 1.85 5,71 
1.4 (PIK3CA  P110 S405F) 169,40 1.86 8,47 
1.5 (PIK3CA  P110 S405F) 166,41 1.86 8,32 
1.6 (PIK3CA  P110 S405F) 109,01 1.87 5,45 
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Table  15.  Nanodrop results of plasmid mini preparations of TP53 K120E and TP53 H179R. 
Sample parallel DNA concentration 
(C) µg/ml 
260/280 
ratio 
Total amount of DNA (µg) 
1.1 (TP53 K120E) 266.24 1.86 12.91 
1.2 (TP53 K120E) 94.02 1.86 4.56 
1.3 (TP53 K120E) 136.01 1.88 6.59 
2.1(TP53 H179R) 134.60 1.87 6.53 
2.2 (TP53 H179R) 148.13 1.86 7.18 
2.3 (TP53 H179R) 107.36 1.88 5.21 
  
The correct mutations were confirmed by sequencing and the Tables 16 and 17 confirmed that 
all bacterial clones contained the mutant plasmids.  
 
Table 16. Sequencing results of PIK3CA P110 S405F plasmid mini preparations Table 14. 
  Sample 
parallel Sequence result, forward Sequence result, reverse 
1.1 PIK3CA S405F, homozygote PIK3CA S405F, homozygote 
1.2 PIK3CA S405F, homozygote PIK3CA S405F, homozygote 
1.3 PIK3CA S405F, homozygote PIK3CA S405F, homozygote 
1.4 PIK3CA S405F, homozygote PIK3CA S405F, homozygote 
1.5 PIK3CA S405F, homozygote PIK3CA S405F, homozygote 
1.6 PIK3CA S405F, homozygote PIK3CA S405F, homozygote 
 
Table 17. Sequencing results of plasmid mini preparations of TP53 K120E and TP53 H179R Table 15. 
Sample 
parallel Sequence results, forward Sequence results, reverse 
1.1 TP53 K120E, homozygote TP53 K120E, homozygote 
1.2 TP53 K120E, homozygote TP53 K120E, homozygote 
1.3 TP53 K120E, homozygote TP53 K120E, homozygote 
2.1 TP53 H179R, homozygote TP53 H179R, homozygote 
2.2 TP53 H179R, homozygote TP53 H179R, homozygote 
2.3 TP53 H179R, homozygote TP53 H179R, homozygote 
 
Electropherograms of the forward- and the reverse sequences shows that the plasmid DNA 
containing the homozygote mutant PIK3CA P110 S405F (Figure 22).   
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Figure 22. Electropherograms of the forward  and reverse  sequence of the mutant PIK3CA P110 S405F. 
The forward sequence is read in 5’→3’ direction and the reverse sequence in 3’→5’ direction. a) PIK3CA P110 
S405F, exon7 forward. b) PIK3CA P110 S405F, exon7 reverse. 
  
Similary is seen for the homozygote mutants TP53 K120E and TP53 H179R, 
electropherograms of the forward and the reverse sequence of plasmid DNA containing the 
mutants (Figure 23). The sequence results of the mutant plasmids generated from the 
mutagenesis were thus confirmed.  
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Figure 23. Electropherograms of the forward and the reverse sequence of the mutant TP53 exon4  K120E 
and the mutant TP53 exon5  H179R. The forward sequence is read in 5`→3` direction and the reverse 
sequence in 3`→5` direction. a) TP53 K120E, exon 4 forward. b) TP53 K120E, exon 4 reverse. c) TP53 H179R, 
exon 5 forward. d) TP53 H179R , exon 5 reverse. 
 
3.6. Plasmid midi preparation 
Clones which contained the right mutant gene were picked for large scale culturing in order to 
isolate DNA midi preparations. The concentrations and total DNA amounts are shown in 
Table 18. The table shows high concentrations, and good quality of DNA. To obtain the 
recommend plasmid concentration for the transfections which is 30 µg of 1 µg/µl, the plasmid 
DNA samples were speedvacced. 
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Table 18. Plasmid DNA concentrations after plasmid midi preparation. 
Sample DNAconcentration 
(C) µg/ml 
260/280 
ratio 
Total amount of DNA (µg) 
PIK3CA P110 S405F  216.74 1.86 ~71.5 
PIK3CA P110 S405F  166.40 1.90 ~54.9 
TP53 K120E 360.12 1.86 72 
TP53 H179R 275.78 1.88 124.1 
TP53 wt 220.39 1.88 50.7 
LacZ 134.01 1.85 45.6 
PIK3CA P110 wt 195.31 1.86 72.3 
PIK3CA P110 E545K 302.99 1.87 75.7 
PIK3CA P110 S405F  145.43 1.86 64 
 
3.7. Transfection of Ba/F3 cells to obtain stable cell lines  
After constructions of plasmids containing mutant genes, the plasmids were transfected into 
the parental Ba/F3 cells by electroporation. As we have confirmed that parental Ba/F3 are 
dependent on IL-3 in the culturing media, they are not Blasticidin resistant. After Blasticidin 
selection the cells were grown in medium without IL3 in order to find out whether the 
mutations were oncogenic. After the transfections, Blasticidin selections and maintenance of 
the cell cultures were done every third day with medium without IL-3. The cell suspensions 
were examined microscopically to visualize changes and cell growth. The cell cultures were 
also photographed. 
 
Figure 24 show pictures of the transfected Ba/F3 cell line TP53 H179R. Seven days after the 
first Blasticidin addition the microscopic examination of the cell culture shows two different 
cell types, viable transfected Ba/F3 cells and dead parental cells. 14 days after the first 
Blasticidin addition, the cells grow fast before they change their morphology on the 29
th
 day. 
The transfection and the Blasticidin selection have worked. It indicates that the mutation 
TP53 H179R is oncogenic because of the presence of living cells after maintenance with 
medium without IL-3. According to the IL-3 experiment, subchapter 3.4, all parental cells 
died after three days without IL-3.    
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Figure 24. Images of the wells with transfected Ba/F3 cell line TP53 H179R. a) Seven days after the first 
Blasticidin addition. The image shows two different cell types, viable transfected Ba/F3 cells and dead parental 
cells. b) 14 days after the first Blasticidin addition. The image shows fast growing living cells and dead cells. c) 
23 days after the first Blasticidin addition. The image shows a few living cells among dead cells. d) 29 days after 
the first Blasticidin addition. The image shows that the cells have changed their morphology. e) 35 days after he 
first Blasticidin addition. It was split 1/2, 29 days after the first Blasticidin addition. The image shows that the 
cells have same appearance as in d). f) 43 days after the first Blasticidin addition. It was split 1/2 38 days after 
the first Blasticidin addition. The image shows that the cells have same appearance as in d). (40 x) magnification 
is used.  
  
Seven days after the first Blasticidin addition of the transfected Ba/F3 cell line PIK3CA P110 
S405F the microscopic examination of the cell culture shows cell suspension with dead cells 
and few living cells (Figure 25). After 14 days after the first Blasticidin addition the viable 
cell number has increased before they have changed their morphology on the 29
th
 day of the 
first Blasticidin addition. The transfection and the Blasticidin selection are sucessfull. It is 
likely that the mutation PIK3CA P110 S405F is oncogenic because of presence of living cells 
after maintance with medium without IL-3. 
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Figure 25. Images of the wells with cultured transfected Ba/F3 cell line PIK3CA P110 S405F a) Seven days 
after the first Blasticidin addition. The image shows cell suspension with dead cells and few living cells. b) 14 
days after the first Blasticidin addition. The number of living cells has increased. c) 23 days after the first 
Blasticidin addition. The image shows both living cells and dead cells. d) 29 days after the first Blasticidin 
addition. The cells have changed their morphology. e) 35 days after the first Blasticidin addition. It was split 1/2 
29 days after the first Blasticidin addition. The cells look the same as the cells in the image d). f) 43 days after 
the first Blasticidin addition. The cell suspension was split 1/2 38 days after the first Blasticidin addition. The 
cells look the same as the cells in the image d). a)-e): (40 x) magnification, f): (20x) magnification. 
 
By microscopic evaluation of the transfected Ba/F3 cell line TP53 K120E we saw only dead 
cells without any changes in the appearance (Figure 26). This indicates that the cell line is not 
oncogenic or that the transfection has not succeeded.  
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Figure 26. Images of the wells with cultured transfected Ba/F3 cell line TP53 K120E. All images show a 
well containing cell suspension with dead cells 21 days, 29 days and 35 days after the first Blasticidin addition. 
(40x) magnification is used.  
  
The PIK3CA P110 E545K is a known oncogenic mutation (personal communication: Gordon 
Mills, M.D. Andersson, Houston, Tx, USA) and was used as a positive transfection and 
viability control. Seven days after the first Blasticidin addition the microscopic examination 
of the cell culture shows cell suspension of dead cells, but on the 21 days after the first 
Blasticidin addition many viable cells were observed (Figure 27). On the 29 days after the 
first Blasticidin addition the cells have changed their morphology. Also here transfection and 
Blasticidin selection have worked. The cell line worked as a positive control.  
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Figure 27. Images of the wells with cultured transfected Ba/F3 cell line PIK3CA P110 E545K a) Seven days 
after the first Blasticidin addition. No visible living cells. b) 14 days after the first Blasticidin addition. The 
image shows no visible cells. c) 21 days after the first Blasticidin addition. The image show many viable cells. d) 
29 days after the first Blasticidin addition. The image shows that the cells have changed their morphology. e) 35 
days after the first Blasticidin addition. The cells were split 1/2 29 days after the first Blasticidin addition. The 
cells look like cells in image d). f) 43 days after the first Blasticidin addition. The cells look like cells in image 
d). a): (20 x) magnification. b)-f): (40x) magnification. 
 
The TP53 wt plasmid was used as a double stranded DNA template in the mutagenesis. 
Figure 28 shows images of the transfected cell line TP53 wt plasmid. On the 21 day after the 
first Blasticidin addition we saw dead cells and few living cells. On the 29 days after the first 
Blasticidin addition we saw only few dead cells and the same observation was done on the 35 
days. The transfection has worked but the cells did not grow without IL-3. 
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Figur 28. Images of the wells with cultured transfected Ba/F3 cell line TP53 wt. a) 21 days after the first 
Blasticidin addition. The image shows dead cells and few viable cells. b) 29 days after the first Blasticidin 
addition. Only few dead cells, no living cells were observed. c) 35 days after the first Blasticidin addition. Only 
few dead cells, no living cells were observed. All images show wells with cell suspension, (40x) magnification. 
 
The PIK3CA P110 wt plasmid was used as a double stranded DNA template in the 
mutagenesis. Figure 29 shows image of the transfected Ba/F3 cell line PIK3CA P110 wt. The 
images shows cell culture with only dead cells without any changes in the morphology.  
   
Figure 29. Images of the wells with cultured transfected Ba/F3 cell line PIK3CA P110 wt. All images show 
wells with cell suspension with dead cells seven days, 14 days. 21 days, 29 days and 35 days after the first 
Blasticidin addition, a) and d) (20x) magnification. b), c) and e) (40x) magnification. 
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The LacZ plasmid was used as a normal control for monitoring the transfection efficiency. 
Cells with the LacZ plasmid were dead (Figure 30) . It worked as a normal control. 
 
Figure 30. Images of the wells with cultured transfected Ba/F3 LacZ. All images show cell suspension with 
dead cells 21days, 29 days and 35 days after the first Blasticidin addition, a) and c) (20x) magnification, b) (40x) 
magnification.  
 
Parental Mock+/- control cells were subjected to electroporation. Mock + is treated with 
Blasticidin and Mock- is not treated with this selection marker. Figure 31a-e) show only dead 
cells as these are not resistant to Blasticidin. Mock – in 31f) is more confluent since it grew 
fast as it was not treated with Blasticidin, but the cells died due to lack of IL-3.  
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Figure 31. Images of the wells in a 48 well plate containing Mock treated Ba/F3 cells with and without 
Blasticidin in the medium. a)-e): The cells were subjected to electroporation and treated with Blasticidin 
(Mock+). a)-e): Cell suspension with dead cells seven days, 14 days, 21 days, 35 days and 43 days after the first 
Blasticidin addition. f): The cells were subjected to electroporation and not treated with Blasticidin  (Mock-). 
Cell suspension with many dead cells. The parental cells divided fast before they died because of lack of IL3 in 
the medium. a) - d) and f) (40x) magnification. e) (20x) magnification. 
  
Figure 32 shows the parental Ba/F3 cell cultures which are not subjected to electroporation. 
Images a) and b) show few dead cells due to the Blasticidin treatment. Images c) and d) show 
many dead Ba/F3 cells. The cell culture was not treated with Blasticidin.  The cells grew fast 
before they died due to maintenance with medium without IL-3.     
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Figure 32. Images of the wells with cultured parental Ba/F3 cells. a) and b) show treatment with Blasticidin, 
c) and d) show no treatment with Blasticidin. a): The image is taken 21 days after Blasticidin addition and shows 
few dead cells. b): The image is taken 35 days after Blasticidin addition and show few dead cells. c) and d) show 
many dead cells. The parental Ba/F3cells divided fast before they died because of lack of IL-3 in the medium. a) 
(20x) and b), c), and d) (40x) magnification.  
 
We wanted to confirm whether the transfected cells were viable and did Trypan blue staining 
and a CTG assay after one week culturing in a 384 plate. Figure 33 show images of cell 
suspensions stained with Trypan blue and confirms that the cells were dead. The CTG results 
showed no luminescence signal in all replicates for all samples and controls (data not shown), 
so the microscopic observations of Trypan blue stained cells were confirmed. This indicates 
that we were not able to create stable cell lines after ~ six week culturing for the transfected 
Ba/F3 cell lines TP53 H179R, PIK3CA P110 S405F and the positive control PIK3CA P110 
E545K. We also cultured a parallel transfected Ba/F3 cell line PIK3CA P110 S405F from a 
separate transfection for ~three months, but this also contained only dead cells.      
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Figure 33.  Microscopic observations of cells viability by using Trypan blue staining (1/2 dilution) of 10 µl 
cell suspension. The images show dead blue stained cells. a) Transfected Ba/F3 cell line TP53 K120E. b) 
Transfected Ba/F3 cell line TP53 H179R. c) Transfected cell line PIK3CA P110 S405F (1. parallel). d) 
Transfected cell line PIK3CA P110 S405F (2. parallel). e) Mock +, negative control. f) Transfected Ba/F3 cell 
line PIK3CA P110 wt, normal control. g) Transfected Ba/F3 cell line PIK3CA P110 E545K, positive oncogenic 
control. a), b), d), f) and g) have (10x) magnification. c) and e) have (20x) magnification. The microscopic filter 
2-0,4 was used in a), d), f) and g) and filter 1-0,4 was used in e).         
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4. Discussion 
4.1. Experimental considerations 
4.1.1. In vitro cell culture of Ba/F3 cells 
The Ba/F3 cell line is used as a model system in cancer research. Ba/F3 cells are fast growing 
suspension cells and therefore the experimental turnaround is both easy and rapid (75). The 
cell line is IL-3 dependent and this property can be exploited in the detection of oncogenic 
mutations. Mutant genes can be expressed in transfected Ba/F3 cells and they may lead to IL-
3 independence (74). The Ba/F3 cell can be used to study the potency of cancer gene 
mutations, and to test for drugs to predict response in the clinic (75). 
 
The purpose of this study was to establish the Ba/F3 model system for testing the oncogenic 
potential of cancer gene mutants in Ba/F3 cell cultures. In this study Blasticidin and IL-3 was 
used as selection markers for the transfected Ba/F3 cells. Blasticidin treatment and 
maintenance of the cell cultures was done for a 10 days period after the transfection to select 
the transfected Ba/F3 cells containing plasmids with Blasticidin resistance. Parental cells 
without plasmid died in this period because they were not resistant to Blasticidin. After the 
selection period the cells were maintained without IL-3. If the transfected Ba/F3 cells started 
to grow after the maintenance without IL-3 in the medium, then they have an oncogenic 
mutation in its genomes. If all the cells in one sample died without IL-3, it indicated that the 
mutation was not oncogenic.  
 
The transfected Ba/F3 cell lines were observed regularly in a microscope. First, we observed 
that the cell line TP53 H179R started to grow fast seven days after the first Blasticidin 
addition. Also the transfected cell line PIK3CA S405F was observed with few living cells at 
the same time, but the living cell number had increased one week later. The transfected 
positive control cell line PIK3CA P110 E545K was observed with growth 21 days after the 
first Blasticidin addition. The transfected Ba/F3 cells where then grown further in an attempt 
to generate stable transfected cell lines. The maintenance started without IL-3 for the first 
experiment about 6 weeks after the last Blasticidin addition, and eight days after the second 
experiment. The maintenance by changing medium without IL-3 should have started three 
days after the last Blasticidin treatment. The delay in changing of medium of viable cell 
cultures may lead to pH changes and lack of nutrients in the cell cultures. The transfection, 
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the Blasticidin selection period and removal of IL-3 from the medium are all stressful for the 
Ba/F3 cells. The change of medium three days after the Blasticidin treatment did not take 
place due to misunderstanding of the protocol. This is the most likably explanation why we 
were not able to create stable cell lines. Other possible reasons could be that there were few 
living cells in the culture, which were washed away while maintaining the cells thus, no cells 
survive. The viable cell cultures were expanded from 48-well plate to six-well plate. It is 
possible that the cells became stressed by changing to this plate format. The Ba/F3 cells grow 
in clusters and by diluting them in six-well format they might be unable to signal to each 
other. However, the positive control was cultured in the 48-well format throughout the period 
and also these cells died. Another possible reason why the Ba/F3 cells died could be that the 
transfected viable cells have lost the plasmids because we cultured without Blasticidin after 
the ten days selection period. We did this according to the protocol obtained from our 
collaborator at M.D. Andersson. Generating stable cell lines can be challenging. For example, 
our collaborator did five experiments before they achieved to get stable clones for the positive 
control PIK3CA E545K and the PIK3CA P110 wt. They did ten experiments without 
establishment of a stable cell line for the negative control LacZ with Plenti 6.3 background. 
An alternative method for the Blasticidin selection was reported by Walters and his colleagues 
(76). Ba/F3 cells were transduced (100) with supernatant containing viral constructs. After 
incubation the cells were selected for Green fluorescence protein marker (GFP) expression by 
cell sorting. GFP positive cells were cultured for five-ten days in medium without IL-3. If the 
Ba/F3 cells with plasmids containing the mutant TP53 K120E, TP53 H179R and PIK3CA 
P110 S405F have expressed GFP marker, we could have selected for expression of GFP by 
cell sorting instead of selection with Blasticidin. The cell viability test could have been done 
right after we observed the cell growth. The cell cultures could have been split in two, one 
part to assess cell viability and one part for further culturing. Then we would have had both 
luminescence values and images of the possible oncogenic mutations. Instead, Trypan blue 
staining and cell viability assay were done on the cell cultures after 3 month for one sample 
and ~ six weeks for two other cell lines and control cell lines. At this point the cells had died. 
This might explain the changes in the cell morphology between 21-29 days after the first 
Blasticidin addition. We found that the TP53 H179R and PIK3CA P110 S405F were possible 
oncogenic mutants. The mutant in the transfected cell line TP53 K120E was non-oncogenic 
assuming that the transfection worked. This cell line was observed with only dead cells after 
culturing with medium without IL-3. These results have to be confirmed by further CTG 
viability testing.  
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4.1.2. Controls used in the experiments 
It is important to have controls at all stages of the experiments as sources of error can be 
identified that can affect the test results. Transfected Ba/F3 cell lines LacZ, TP53 wt, PIK3CA 
P110 wt, Mock treated  parental Ba/F3 cells and parental Ba/F3 cells with and without (+/-) 
Blasticidin were used as negative controls, whereas PIK3CA E545K where used as a positive 
control in the experiments. Mock treated Ba/F3 cells (+/-) Blasticidin did not contain any 
plasmids, but were subjected to electroporation. Comparison of these negative controls 
together with parental Ba/F3 cells (+/-) Blasticidin without electroporation could tell us if the 
electric shock have affected the parental cells. The LacZ control was confluent with living 
cells after the last Blasticidin addition. After removing IL3 from the medium the cells died. 
The results from the cell growth experiment of parental cells with and without IL-3 showed 
that after three days without IL-3, there were no viable cells left in the culture. The image in 
Figure 30 a) shows only dead cells from the 21 day after the first Blasticidin addition. This 
negative control gave us information about how the selection markers have worked in our 
experiment. It also confirmed the fact that cells cannot survive without IL-3 unless they carry 
an oncogenic mutant. The luminescence value from the cell viability test of the negative 
control is useful for comparison for transfected mutant Ba/F3 cells. The Ba/F3 cell line 
PIK3CA P110 wt was observed without any living cells throughout the culturing. This was as 
expected since the transfected Ba/F3 cells contained wild type plasmids.  
 
The transfected Ba/F3 cell lines TP53 wt grew more slowly compared to the other cell lines 
after the transfection. A possible explanation was that these cells did not tolerate the 
transfection as good as the others. Few living cells were observed 21 days after the first 
Blasticidin addition (Figure 28a). This observation was unexpected since the transfected 
Ba/F3 cells contained wild type plasmids and should not have been able to grow without IL-3. 
The most probable explanation could be that there was some IL-3 left in the medium because 
of lower consumption of IL-3. That might explain why the TP53 wt transfected cells started to 
grow after a while, but died when we changed medium without IL-3 every third day. On the 
29
th
 day after the first Blasticidin addition we observed only few dead cells left in the cell 
suspension. Many living transfected cells were observed in the positive oncogenic control 
PIK3CA E545K 21 days after the first Blasticidin addition. Some transfected cell lines with 
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mutants with oncogenic potential use longer time before they start growing after the last 
maintenance with IL-3.  
4.1.3. Utilization of the Ba/F3 model system  
Warmuth and his colleagues (75) point out that the Ba/F3 cells properties as fast growing 
suspension cells makes this cell line ideal for automatic culturing systems. Generation of 
cellular potency and selective drug profile can be achieved within one - two weeks (78). They 
further suggested that the Ba/F3 method might be an alternative to the more lab intensive and 
less sensitive fibroblast or epithelial transformation assays (75). It was easy to maintain the 
cultured Ba/F3 cells because they were suspension cells. The cell culture was easy to grow 
and it took only two weeks to get optimal confluence level before the experiments could 
starts. In the present study, the Ba/F3 cells were transfected by electroporation. An alternative 
transfection method is to use a viral system with high titer lentivirus generated by 
cotransfection of HEK293FT cells with viral constructs. Ba/F3 cells would then be transduced 
by viral supernatant, incubated without IL-3 before viability testing (61). Walters et al. used 
virus transfection of Ba/F3 cells combined with cell sorting of GFP-positive cells before 
further analyses (76). Lentivirus vectors have the ability to mediate stable expression and 
mediate potent transduction (101) into diving and non-diving cells both in vivo and in vitro 
(100). The transfection efficiency might be better with lentivirus. The laboratory facility must 
have a higher security level by using a viral system for the transfections. The equipment and 
the optimized conditions for the electroporation procedure were the same as our collaborators 
used at the M.D. Andersson. The Ba/F3 cells were easy to transfect by electroporation and the 
success rate is in general ~ 40 % by using the Neon 
TM
 transfection system according to the 
collaborators at M.D. Andersson. The first landmark experiment on Ba/F3 cells was done by 
Daley et al. in 1988 (74). They managed to render Ba/F3 cells IL-3 independent by the 
oncogenic fusion kinase Bcr-Abl. Since then the Ba/F3 model system has been used of several 
laboratories and many studies have been done with the Ba/F3 cells (61;76;78;102;103). Most 
of the works have been focused on studies of oncogenic potential of kinase mutations (such as 
mutations in JAK 1,2,3, ERBB 2,3,4). Many studies have also been done to on determination 
the efficacy of kinase drug inhibitors and to predict clinical response to drugs. The model 
system is also a valuable tool in studying signaling mechanisms downstream of mutant 
kinases (75).     
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In our study we managed to establish the model system and we did found two possible 
oncogenic mutations. In addition, we found one passenger mutation. We did not succeed to 
establish stable cell lines of the two cell lines with oncogenic potential. If we do drug testing 
on them in the future, we have to establish stable cell lines as the transfection efficiency on 
Ba/F3 cells on our electroporation system is not high enough. We get most reliable results 
from drug screening by testing drugs on stable oncogenic clones. A stable cell line is created 
when the “gene of interest” has been integrated in the host genome and multiplied. Together 
with the host genetic material it can be divided into daughter cells and remain intact for a long 
period. An unstable cell line can lose “the gene of interest” and the experiments become 
unsuccessful.  
 
This model system gives a possibility to test for oncogenic potential for cancer gene 
mutations found in patients. For example, mutants may be identified by deep sequencing of 
the tumor, and the Ba/F3 model system can be used to test the oncogenic potential of the 
identified mutation. The oncogenic mutations may then be further tested with drugs to find 
targeted therapy against the particular mutants. It may also be possible to introduce up to three 
mutations in one gene in the mutagenesis. Another possibility could be to assays with two 
different mutant genes. Then the Ba/F3 cells have to be transfected with two different mutant 
vectors that have different selection markers.  
4.1.4. Other methods to study oncogenic mutations 
There are other methods to test the oncogenic potential of mutations. For example, traditional 
in vitro kinase assay measures the kinase activity. If the gene encoding the kinase has a 
mutation, the control mechanism of the kinase can be disturbed. The kinase becomes active 
and it phosphorylates the substrate continuously. The phosphorylated substrate is labeled with 
radioactive ATP before it can be visualized by autoradiography (104). Another method is the 
soft agar formation assay. Transfected cells expressing mutants or wild type genes are seeded 
on a top layer of 0,4 % agarose. The bottom layer of the well contains higher concentration of 
agarose. After two-three weeks maintenance, the colonies are stained with crystal violet and 
counted. The colony numbers describe the growth rate of the transfected cells (105). This is 
an assay for anchorage-independent growth which means that for example cancer cells can 
grow and form colonies independent of each other.   
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A novel system to study and verify oncogenic capacity of mutations in the kinome and 
phosphatome was published by Kleppe and colleagues (106). They established a model 
system based on a mouse CD4+ and CD8+ T-cell line (named MOHITO for MOuse 
Hematopoietic Interleukin dependent cell line of T-cell Origin) to study oncogenic signaling 
of T-cell malignancies. MOHITO cells are dependent on both Interleukin 2 (IL-2) and 
Interleukin 7 (IL-7) but the latter cytokine is the major survival and proliferation stimulus. 
MOHITO cells are transduced with a bicistronic BCR-ABL1-IRES-GFP construct which 
allows translation of both BCR-ABL1 and GFP proteins. The initial fraction of GTP positive 
cells was 30%. After IL-7 withdrawal a constant increase of GTP positive clones were 
observed and the transduced cells take over. Protein analyses showed high level of 
autophosphorylated BCR-ABL1 and phosphorylation of its downstream target Stat5. 
Transformed cells became sensitive to Imatinib, which induced cell death and blocked 
proliferation (106). In this way Kleppe and colleagues could compare the signaling 
downstream of oncogenic kinases in the B- and the T-cell context. This model system can be 
used in the same manner as the Ba/F3 method. It is a similar system, MOHITO is for the T-
cell signaling and Ba/F3 cells are for the B-cells signaling. 
 
Shah et al. worked with infusion of Ba/F3 cells with stable luciferase expression into mouse 
in a kinase inhibitor resistance study (103). They first characterized the Imatinib-resistant 
Ba/F3 cells with BCR-ABL mutants in vitro. Then they moved to the in vivo experiments by 
testing of growth inhibition of Imatinib-resistant mutant BCR-ABL-expressing Ba/F3 by the 
drug BMS-354825.    
4.2. Biological considerations 
Stratton and colleagues described a driver mutation as a mutation that conferred growth 
advantage on the cancer cell. The passenger mutation has no clonal growth advantage and do 
not contribute to the tumor development (2). In the literature the genes that harbor few or no 
driver gene mutations have been labeled as driver genes (67). These are genes which are 
epigenetically altered, underexpressed or overexpressed in the tumor and may play an 
important role in the neoplastic process. Vogelstein and colleagues suggested categorizing 
driver genes as either “Mut-driver genes” or “Epi-driver genes”. Mut-driver genes contain 
sufficient number or type of driver gene mutations to distinguish them from other genes. Epi-
driver genes are altered through chromatin modification or in DNA methylation which persist 
when the tumor cells divides (67). 
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The mutations tested in our study were from breast tumor samples used in two mice xenograft 
models established in our institute. These xenograft models have also been studied for 
example on metabolic, genomic and transcriptomic levels (107;108). The mutations that we 
tested are in the PIK3CA and TP53 genes. These are two of the most frequently altered genes 
in breast cancer (65;109). Mutation of PIK3CA can lead to constitutive activation. The 
majority of the genes in the PI3K pathway are often mutated or amplified in many types of 
cancer. This signaling cascade regulates proliferation, growth and survival (109). About 23% 
of the breast cancers have mutations in the tumor suppressor gene TP53. The wild type p53 
has an important role as a transcriptional factor induced by stress. It can promote cell cycle 
arrest, apoptosis and senescence and is a potent tumor suppressor. An oncogenic mutation in 
the TP53 gene can lead to increased cell proliferation. Levin and Oren have found that TP53 
mutation is found a late event and presumably play a part in the progression to invasive, 
advanced and metastatic disease (53).  
 
The somatic mutations in tumor samples are mostly missense and heterozygous. Mutations 
generally result in loss of function. The mutated allele loses its function whereas the wild type 
allele retains the function. The mutant TP53 may interact with the wild type allele and mask 
the function of wild type allele in a dominant negative fashion. In some cases the mutated 
protein might show gain of function by acquiring novel functions. This leads to increased 
proliferation of abnormal cells. Codon 179 in the TP53 gene is reported as a hotspot region in 
breast cancer (110). The mutation TP53 H179R, Histidine to Arginine found in one of the 
xenograft breast tumor is reported in 0,63% of the total mutated cases (18 of a total of 2878 
mutations in breast cancer) (111). This mutation is reported to have both dominant-negative 
activity and gain of function in various functional assays. The TP53 K120E is a rare mutation 
and only 2 breast cancer cases are reported to have this mutation (of a total of 2878 mutations 
reported) (111). Few functional studies on this mutation associate it with loss of function. 
These data support our findings that TP53 H179R is an oncogenic mutation and that TP53 
K120E is non-oncogenic. Brachmann and colleagues predicted correlation between the TP53 
mutations in cancer and dominant-negative activity on TP53 mutations in a yeast assay (112). 
They studied the same codon, but with different amino acid change. The oncogenic mutation 
PIK3CA P110 S405F was found in the same xenograft tumor as the non-oncogenic TP53 
K120E mutation and PIK3CA seems to be a driver gene in this xenograft tumor. The mutation 
PIK3CA P110 S405F is in the C2 domain in exon 7. In addition to hotspots in exon 9 and 20, 
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a third hotspot region in exon 7 was reported in the PIK3CA gene. One study reported a 
mutant frequency of seven of a total number of 292 breast cancer tumor samples (2,4%) (69). 
Most of the mutation screening on PIK3CA have been done in the hotspots in exon 9 (Helical 
domain) and exon 20 (Kinase domain) and few has screened exon 7. The PIK3CA mutation 
screening should also include exon 7 since “important” mutations maybe missed. Based on 
our findings, the PIK3CA S405F seems to be an oncogenic mutation. In a metastudy of 100 
breast cancer tumors done by Stephens and his colleagues, they found that the maximum 
numbers of oncogenic mutations in an individual breast cancer was six, and 28 cases had only 
a single driver. They found driver mutations in 40 genes and 73 combinations of mutated 
genes. This illustrates the genetic diversity in breast cancer (65). In some cases one mutation 
with oncogenic potential can be enough in the development of cancer. It is possible that the 
oncogenic mutations we found in this study, may lead to breast cancer progression, however 
more testing have to be done.    
 
Vogelstein and colleagues state that all known driver genes can be classified into 1 - 12 
pathways and that they can be organized into 3 core cellular processes: the cell survival, the 
genome maintenance and the cell fate (Figure 34) (67). 
 
 
 
Figure 34. Cancer cell signaling pathways and the cellular processes they regulate (67). All driver genes can 
be classified into 1-12 pathways (middle circle) that confer a selective growth advantage (inner circle). These 
pathways can be further organized into three core cellular processes (outer circle).   
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The PIK3CA gene belongs to the cell survival and the TP53 to the genome maintenance 
pathways (67). The cell signaling pathways are a complex network with many parallel and 
regulation systems at different levels. Most of the signaling pathways incorporate feedback 
loops to turn on and off the signaling cascades. By having a positive feedback loop, the output 
of a process stimulates its own production, and for a negative feedback loop the output 
inhibits its own production (113). One example is the p53-MDM2 autoregulatory feedback 
loop (53). A positive regulation is when p53 as a transcriptional factor target MDM-2 and the 
MDM-2 expression increases. MDM2 can inhibit p53 through binding to its transactivating 
domain. 
 
Another regulation of signaling cascades is cross-talking and the most common is the one 
between the substrates for different kinases in several pathways. The substrates can also be 
shared between different pathways and interact with other signaling cascades. There are 
multiple cross-talk mechanisms from the PI3K pathway to other signaling pathways like the 
Ras-MAPK pathway. PI3K pathway can also modulate Raf which is a Ras target. AKT 
phosphorylates C-Raf and B-Raf and this inhibition reduces the activity of the MAPK 
pathway. It is important for proper regulation of differentiation in some tissues and for cell 
survival (55).  
 
Cancer cells can have oncogenic pathway redundancy. Multiple pathways are able to assist 
tumor growth and development. For example PI3K/AKT/mTOR and MEK/ERK signaling 
pathways cooperate in many tumors to drive growth and survival of the tumor (114). Due to 
activation of alternative cascades, feedback loops and cross-talks in the signaling network a 
single targeted therapy approach can fail. Use of drug combinations can inhibit the whole 
pathway and prevent feedback or cross-talks mechanism (55). Combination therapy was 
found to be more efficient in the inhibition of tumors in mice in a study done by Junttila et al. 
(46). By targeting two independent signaling pathways with two or more drugs there is 
smaller chance to develop resistance against the treatment (67). The small molecule kinase 
inhibitors are binding the kinase as a small ligand or interfering with the enzymatic activity of 
the protein (67). PI3K signaling pathway is the most frequently targeted pathway (51). 
Boyault et al. showed that the majority of the mutations in breast cancer tumors occurred in 
the TP53 and PI3K pathway. Targeted therapies of these two pathways can provide benefit for 
a substantial proportion of breast cancer patients (115).   
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The mutation frequency we found in the IAC database for the Tp53 H179R was 0,63%. This 
might be too low to do further in vivo experiments from mice to human clinical trials. It could 
be a possibility to use the Ba/F3 model system to test for life-pro-longing drugs for patients 
with metastasis where no other treatments work. First, deep sequencing can be done on the 
tumor sample from the patient to identify candidate mutations for functional testing. The 
mutant gene can be tested for oncogenic potential in the Ba/F3 assay. If the mutant gene is 
oncogenic we can do further drug testing in this system. The most effectively drug inhibiting 
the proliferation of the transfected Ba/F3 cells with the oncogenic mutant, can then be used to 
treat the patient. The Ba/F3 assay has many sub-procedures before it come to the transfection 
and the cell culturing part; therefore it is not a quick method. It will take too long time to do 
drug experiments of the oncogenic mutation in mice experiments for the metastatic patient 
group.  
 
The two established breast cancer xenograft models are described as basal-like and luminal-
like phenotype based on histopathological characteristics, ER status and profound diversity in 
gene expression pattern (107). Moestue and colleague found effect of long term treatment of 
PI3K inhibitors MK2206 or BEZ235 in the tumor-bearing mice which have the basal-like but 
not in the luminal-like phenotype (116). In our study we found the oncogenic mutations 
PIK3CA S405F and the non-oncogenic mutation TP53 K120E in the tumor from the basal-
like and the oncogenic mutation TP53 H179R in the tumor from the luminal-like xenograft 
mice. The study from Moestue showed treatment response in the xenograft which has an 
oncogenic mutation in the PIK3CA gene. This strengthens our findings that the PIK3CA 
mutation was oncogenic in the BaF3 model system. Other treatment regimens can be used for 
testing in these two xenograft models. When the results from our study are confirmed, they 
can be used for further planning and result evaluations of the experiments on these two 
xenograft models.  
 
Some issues were raised by Yi et al. about clinical use of genomic data for personalized 
cancer therapy. Both non-functional passenger mutations and detection of artifacts variants of 
no significance can be identified from the sequence results (105). If therapeutic decisions 
were taken from these analyses it might results in therapeutic failure if the functional 
importance of the mutants is not tested upfront. Another issue is that novel gene variants of 
unknown significance are being discovered in large-scale studies (117-119). Low frequency 
of non-hotspot mutations in PIK3CA, KRAS, NRAS and ERBB2 have been shown to have 
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transforming activity in functional analyses (105). “Methods based on mutation frequency can 
only prioritize genes for further analysis but cannot unambiguously identify driver genes that 
are mutated at low frequencies” (67).  
 
Breast cancer is heterogeneous and consists of many different diseases. It is unique to each 
woman in a complex biological system. A correct diagnosis and etiology-matched treatment is 
based on identification of driving genetic events within the context of the tumor cell of origin 
(51). Experimental model systems are therefore important in studying mechanisms of breast 
cancer and to develop better treatment strategies.   
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5. Conclusions 
In this master thesis, we successfully established the Ba/F3 method in our laboratory. The 
parental Ba/F3 cell line is an IL-3 dependent murine pro lymphoid B-cell line. This cell line 
can be used as a model system to assess the oncogenic potential of cancer gene mutations, as 
well as their downstream signaling. Parental BaF3 cells are transfected with cancer gene 
mutations by electroporation, and oncogenic mutants will continue to grow without IL-3. 
Three mutations and controls were tested for oncogenic potential by using this method. The 
transfected Ba/F3 cell line with mutations TP53 H179R, PIK3CAP110 S405F and 
PIK3CAP110 E545K were oncogenic, as evaluated microscopically. TP53 K120E was non-
oncogenic because no cell growth was observed in the absence of IL-3. The negative controls 
TP53 wt, PIK3CA wt, LacZ, Mocks +/- Blasticidin and parental Ba/F3 cells +/- Blasticidin 
did not grow without IL-3. According to the cell viability tests, the cells were not viable after 
1.5-3 months incubation, indicating that we were unsuccessful in creating stable cell lines. All 
microscopic observations have to be confirmed with a new cell viability assay.   
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6. Future aspects. 
We successfully established the Ba/F3 model system in our laboratory. The microscopic 
evaluations of the two oncogenic mutations TP53 H179R and PIK3CAP110 S405F and the 
non-oncogenic TP53 K120E in this study have to be confirmed by a new cell viability assay. 
We would then be able to quantify the viable cells using a luminescence reader. This would 
be more accurate than visual microscopic evaluations. It is possible to create stable cell lines 
of the transfected Ba/F3 cells with oncogenic mutations and the controls. We would then be 
able to do further experiments on the mutants tested, such as drug experiments. By using the 
Ba/F3 model system, targeted therapy against the oncogenic mutations can be tested. Deep 
sequencing of patients’ cancer genome is getting more common. The BaF3 system can be 
used for testing the oncogenic potential of mutated genes identified by sequencing. It is now 
easier to get access to next generation sequencing results from breast cancer tumor materials 
at our department. By using this functional method for example on new mutations found in 
several patients and also on tumor samples showing aggressiveness, we can assess if the 
mutations are oncogenic or not. The BaF3 method can be further developed for testing two 
different genes with mutations at the same time by using two different vectors with different 
selection markers. Most of the breast cancer patients have tumor genomes which are complex 
and deregulated. To test for mutations in multiple genes at the same time would mimic the in 
vivo situation. It is also possible to test up to three mutations for one gene at the same time by 
using this method.   
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Appendix A  
Table A1. Reagents and equipments  
Name  Producer Supplier Cat.nr. 
Corning Petri dish Corning Incorporated, 
NY USA 
Fisher Scientific 430167 
RPMI media + L-Glutamine GIBCO
®  
 Life Technologies
TM
 21875-091 
FBS GIBCO
®  
Invitrogen
TM
, 
USA 
Life Technologies
TM
 26140 
IL-3 GIBCO
®
, USA Life Technologies
TM
 PMC0034 and 
PMC0035 
Blasticidin S HCl Invitrogen Life Technologies
TM
 R210-01 
DMSO Thermo Scientific, USA Fisher Scientific 20688 
Waterbath,  sub aqua 12 puls Grant VWR International AS - 
Saarstedt tube 15 ml Saarstedt Saarstedt 62.554.502 
Saarstedt tube 50 ml Saarstedt Saarstedt 62.547.254 
Cryo tube 2 ml Greiner bio-one , 
Germany 
BD Biosciences 126277 
Centrifuge, Rotina 420, 
Hettich Zentrifugen  
Andreas Hettich GmbH 
& Co.KG, Germany 
DJB Labcare - 
Light Microscop, Axiovert 
40 CFL 
Zeiss - - 
Ampicillin  sodium salt GIBCO
®
, USA Life Technologies
TM
 11593-027 
TP53 wt Plasmid  Origene, USA Bionordika CW102028 
MycoAlert
R
 Mycoplasma 
Detection kit 
Lonza, USA Medprobe LT07-218 
Nuclon 96 microtiterplate 
  
Nunc, Denmark Thermo Scientific 136101 
Bürker Chamber Assistent VWR - 
Trypan Blue stain 0,4% Gibco Invitrogen 15250-061 
CTG Promega , USA Nerliens Meszansky  G7571/2/3 
QIAprep
R
 spin miniprep kit Qiagen Qiagen, Norway 27104 
 
Nanodrop 
Saween Werner Saween Werner - 
Falcon tube BD Biosciences BD Biosciences 352059 
Wallac 1450 Micro Beta 
TriLux luminescence 
Counter 
Perkin Elmer, USA - - 
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Name  Producer Supplier Cat.nr. 
MicroBeta  Windows 
Workstation 
Perkin Elmer, USA - - 
DPBS, Dulbecco`s Phospate 
buffered Saline – CaCl2,  - 
MgCl2 
GIBCO
®
, USA Life Technologies
TM
 14190-169 
Distilled Water, 
DNase/RNase Free 
GIBCO
®
, USA Life Technologies
TM
 10977-049 
Applied Biosystems 3730 
DNA analyzer 
Applied Biosystems, 
USA 
Life Technologies
TM
 - 
Sequencing Analysis 
software v5.2 
Applied Biosystems, 
USA 
Life Technologies
TM
 - 
BigDye
R
Direct Sequencing 
Kit 
Applied Biosystems, 
USA 
Life Technologies
TM
 - 
DNA Engine tetrad 2 Peltier 
Thermal Cycler) 
Bio-Rad laboratories, 
USA 
Bio-Rad - 
øx 174-Hae III digest TaKaRa Clontech 3405 A 
GeneGenius Bio Imaging 
System 
Syngene VWR - 
BigDye
R
XTerminator
TM
 
Purifiaction  Kit 
Applied Biosystems 4376484 4276484 
96-well plate septa Applied Biosystems Life Technologies
TM
 4315933 
3730 DNA analyzer Applied Biosystems Life Technologies
TM
 - 
POP-7
PM
 Performance 
Optimized Polymer 
Applied Biosystems Life Technologies
TM
 4363929 
Sequencing analyzes 
software v5.2 
Applied Biosystems Life Technologies
TM
 - 
Sequencing primers Eurogentec Bionordica - 
Neon
TM 
transfection System Invitrogen Life Technologies
TM
 - 
DNA120 SpeedVac
®
 
ThermoSavant  
- Dip.Ing.Houm - 
BD Falcon 250 ml 
Erlenmeyer Culture Flask 
BD Biosciences, USA BD Biosciences 355119 
Glyserol, minimum 99% SigmaAldrich VWR G5516 
Eppendorf  tube ,1,5 ml Eppendorf, Germany VWR 003 0123.328 
100 µl Neon™ Kit Invitrogen Life TechnologiesTM - 
6 well plate Thermo Scientific, 
Denmark 
Thermo Scientific, 
Denmark 
140675 
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Name  Producer Supplier Cat.nr. 
48 well plate Thermo Scientific, 
Denmark 
Thermo Scientific, 
Denmark 
150687 
Steril filter, 0,2 µm Millipore, Ireland Millipore - 
GelRed 
TM
 nucleic Acid Gel 
Stain 
Biotium, USA - 41003-1 
 
 
  
 84 
 
 
Appendix B  
Table B1. Ba/F3 culture medium. Calculated volumes for different total amount of the medium. 
500 ml: 
 
250 ml: 
 
RPMI ( 13 X 35ml +20 ml) 475 ml RPMI 6 x35 ml+27,5 ml) 
237,5 
ml 
FBS ( Final concentration 
5%) 25 ml 
FBS ( Final concentration 
5%) 12,5 ml 
IL-3( 100 ng/ml) 25 ul IL-3 (100 ng/ml) 12,5 ul 
    
    125 ml: 
 
62,5 ml: 
 
RPMI ( 3x35 ml +13,7 ml) 
118,7 
ml RPMI (1x35 ml + 27,5 ml) 59,3 ml 
FBS ( Final concentration 
5%) 
6,25 
ml 
FBS ( Final concentration 
5%) 3,1 ml 
IL-3 (100 ng/ml) 6,25 ul IL-3 (100 ng/ml) 3,1 ul 
    
    
    31,2 ml 
   
RPMI 
29.7 
ml 
  FBS ( Final concentration 
5%) 1,6 ml 
  IL-3 (100 ng/ml) 1,6 ul 
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Appendix C 
 
DNA sequencing on the ABI 3730 DNA Analyzer 
 
Kits: BigDye
®
 Direct Cycle Sequencing Kit and BigDye
®
 XTerminator
™
 Purification Kit 
Use: DNA sequencing 
Sample: Genomic DNA (5 ng/μl)  
Principle: Chapter 1 “Introduction to DNA Sequencing” in the DNA Sequencing by Capillary  
Electrophoresis, Applied Biosystems Chemistry Guide
1
 
 
Chemical/reagent Supplier 
Ordering 
information 
Lab location User location 
10x 3730 Buffer with 
EDTA 
Applied 
Biosystems 
4335613 
K02-107 
PCR lab I (fridge) 
K02-078 
Instrument lab 
φX 174-Hae III digest TaKaRa 3405 A 
K02-107 
PCR lab I (fridge) 
K02-078 
Instrument lab 
Big Dye
®
 Direct Cycle 
Sequencing Kit 
Applied 
Biosystems 
4458688 
K02-088 
DNA lab (freezer 4) 
K02-088 
DNA lab 
BigDye
®
 
XTerminator
™ 
Purification Kit 
Applied 
Biosystems 
4376484 
K02-085 
Cooling room 
K02-088 
DNA lab 
Bromophenol blue 
Bio-Rad 
Laboratories 
161-0404 
K02-097 
Chemical room 
K02-097 
Chemical room 
Certified
™
 Molecular 
Biology Agarose 
Bio-Rad 
Laboratories 
161-3102 
K02-097 
Chemical room 
K02-097 
Chemical room 
DNase/RNase free 
H2O 
GIBCO 10977-35 
K02-088 
DNA lab 
K02-088 
DNA lab 
EDTA disodium salt BDH
®
 100935V 
K02-097 
Chemical room 
K02-097 
Chemical room 
Ficoll
®
 PM 400 
Sigma-Aldrich
®
 
Norway AS 
F4375 
K02-097 
Chemical room 
K02-097 
Chemical room 
Glacial Acetic Acid MERCK 100063 
K02-097 
Chemical room 
K02-097 
Chemical room 
  
                                                 
1
 The Applied Biosystems Chemistry Guide may be downloaded from 
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_041003.
pdf  
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Chemical/reagent Supplier 
Ordering 
information 
Lab location User location 
GelRed
™
 Nucleic Acid 
Gel Stain 
Biotium 41003-1 
K02-107 
PCR lab I (fridge) 
K02-107 
PCR lab I 
POP-7
™
 Performance 
Optimized Polymer 
Applied 
Biosystems 
4363929 
K02-107 
PCR lab I (fridge) 
K02-078 
Instrument lab 
Trizma
®
 base 
Sigma-Aldrich
®
 
Norway AS 
T1503 
K02-097 
Chemical room 
K02-097  
Chemical room 
Laboratory equipment 
96-well plate septa 
Applied 
Biosystems 
4315933 K02-107 PCR lab I 
Bijou bottle 129B, 
7ml, Sterilin 
Heger 10036 K02-088 DNA-lab 
Disposable Scalpels  Swann-Morton 0503 K02-088 DNA lab 
Domed Cap Strip 
Thermo 
Scientific 
AB-0602 K02-088 DNA lab 
Eppendorf PCR Clean 
Safe-Lock Tubes 1,5 
ml 
Eppendorf 0030 123.328 K02-088 DNA lab 
Gloves (nitrile) 
OUS 
storageroom 
RH20203 (Small)/ 
RH20201(Mediu
m) 
K02-088 DNA lab 
MicroAmp
™
 Optical 
96-Well Reaction Plate 
with Barcode 
Applied 
Biosystems 
4306737 K02-088 DNA lab 
Reagent Reservoir 50 
ml 
Costar 4870 K02-088 DNA lab 
Therma-Fast
®
96, Non-
Skirted 
Thermo 
Scientific 
AB-0600/G K02-088 DNA lab 
Instruments             
3730 DNA Analyzer 
Applied 
Biosystems 
- K02-078 Instrument lab 
DNA Engine Tetrad 2 
Peltier Thermal Cycler 
Bio-Rad 
Laboratories 
- K02-107 PCR lab I 
Eppendorf Centrifuge 
5804 
Eppendorf - K02-107 PCR lab I 
Eppendorf Centrifuge 
5810R 
Eppendorf - K02-088 DNA lab 
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Instruments (continue)        
Eppendorf Mini Spin
®
 Eppendorf - K02-088 DNA lab 
GeneGenius Bio 
Imaging System 
Syngene - K02-107 PCR lab I 
Illumina High-Speed 
Microplate Shaker 
Illumina - K02-078 Instrument lab 
Powerpac 300 
Electrophoresis Power 
Supply 
Bio-Rad 
Laboratories 
- K02-107 PCR lab I 
SeqScape v.2.7 
Applied 
Biosystems 
- Personal computer 
Sub-Cell
®
 Model 192 
Bio-Rad 
Laboratories 
- K02-107 PCR lab I 
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Safety precautions 
Chemical/reagent 
Laboratory 
classification 
request 
User 
location 
R-phrases 
S/P-
phrases 
Classification 
according to 
danger 
10x 3730 Buffer with 
EDTA  
SN1 
K02-078 
Instrument 
lab 
  
1 
Agarose 
CAS: 9012-36-6 
SN1 
K02-097 
Chemical 
room 
  
1 
BigDye
® 
Direct M13 
Forward primer 
SN1 
K02-088 
DNA lab 
  
1 
BigDye
® 
Direct M13 
Reverse primer 
SN1 
K02-088 
DNA lab 
  
1 
BigDye
® 
Direct PCR 
Master Mix 
 
Hazardous 
substances: 
Hydroxylated 
Organoamine  
(1-10%) CAS: 
Proprietary 
 
Glycerol (10-30%) 
CAS: 56-81-5 
SN1 K02-088 
DNA lab 
 
 
 
 
Xi; 
R36/37/38 
 
Xi; 
R36/37/38 
 
 
 
 
S24/26/37/
60 
 
S24/26/37/
60 
 
2 
 
Wear personal 
protective 
equipment 
BigDye
® 
Direct 
Sequencing Master 
Mix 
 
Hazardous 
substances: 
Hydroxylated 
Organoamine  
(1-10%) CAS: 
Proprietary 
 
 
Glycerol (10-30%) 
CAS: 56-81-5 
SN1 K02-088 
DNA lab 
 
 
Xi; 
R36/37/38 
 
 
Xi; 
R36/37/38 
 
 
S24/26/37/
60 
 
 
S24/26/37/
60 
 
2 
 
Wear personal 
protective 
equipment 
Control DNA CEPH SN1 
K02-088 
DNA lab 
  1 
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Chemical/reagent 
Laboratory 
classification 
request 
User 
location 
R-phrases 
S/P-
phrases 
Classification 
according to 
danger 
DNase/RNase free 
H2O 
SN1 
K02-088 
DNA lab 
  
1 
Wear gloves! 
Gel Loading buffer  
(0,1% bromophenol 
blue) 
SN1 
K02-107 
PCR lab I 
  1 
GelRed
™
 Nucleic Acid 
Stain, 10,000 x in 
DMSO  
 
Hazardous 
substances: 
DMSO CAS: 67-68-5 
SN1 K02-107 
PCR lab I 
 
 
 
Xi; 
R36/37/38 
 
 
S23/26/36 
2 
Handle with care. 
The substance has 
not been fully 
tested. 
SAM
™
 Solution 
 
Hazardous 
substances: 
Trade Secret (1-10%) 
CAS: Proprietary 
 
Trade Secret (10-30%) 
CAS: Proprietary 
SN1 K02-088 
DNA lab  
 
Xi; 
R36/37/38 
 
Xi; R36/38 
 
 
S24/26/37/
60 
 
S24/26/37/
60 
 
2 
 
Wear personal 
protective 
equipment 
TAE buffer (50x) 
 
Hazardous 
substances: 
Trizma
®
 base 
CAS: 77-86-1 
 
Glacial Acetic Acid 
CAS: 64-19-7 
 
EDTA dinatriumsalt 
dihydrat 
CAS: 6381-92-6 
SN2 K02-107 
PCR lab I 
 
 
Xi; 
R36/38/43/ 
52/53  
 
 
 
 
S24/26/37/
61 + P338 
 
 
2 
TAE buffer (1x) SN1 
K02-107 
PCR lab I 
  1 
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Chemical/reagent 
Laboratory 
classification 
request 
User 
location 
R-phrases 
S/P-
phrases 
Classification 
according to 
danger 
XTerminator
™
 
Solution 
 
Hazardous 
substances: 
Trade Secret (10-30%) 
CAS: Proprietary 
 
Trade Secret (10-30%) 
CAS: Proprietary 
SN1 K02-088 
DNA lab 
 
 
Xi; R36 
 
Xi; 
R36/37/38 
 
 
S24/26/37/
60 
 
S24/26/37/
60 
 
2 
 
Wear personal 
protective 
equipment 
 
Xi = irritant. R10: Flammable. R35: Causes severe burns. R36: Irritating to eyes. R37: 
Irritating respiratory system. R38: Irritating to skin. R43: May cause sensitization by skin 
contact. R52: Harmful to aquatic organisms. R53: May cause long-term adverse effects in the 
aquatic environment. S23: Do not breathe gas/fumes/vapor/spray. S24: Avoid contact with 
skin. S26: In case of contact with eyes, rinse immediately with plenty of water and seek 
medical advice. S36: Wear suitable protective clothing. S37: Wear suitable gloves. S45: In 
case of accident or if you feel unwell, seek medical advice immediately (show the label where 
possible). R51: Toxic to aquatic organisms. R52: Harmful to aquatic organisms. S60: This 
material and its container must be disposed of as hazardous waste. S61: Avoid release to the 
environment. Refer to special instructions/safety data sheet. P338: Remove contact lenses if 
present and easy to do and continue rinsing. 
 
 
Disposal 
Chemical/reagent Disposal number 
10x 3730 Buffer with EDTA diluted 1:10 Not dangerous waste 
Agarose gel (1,5%) Yellow risk container 
BigDye
® 
Direct Cycle Sequencing Kit 
These materials and its containers must be disposed of 
as hazardous waste. Yellow risk container. 
BigDye
®
 XTerminator
™
 Purification Kit 
These materials and its containers must be disposed of 
as hazardous waste. Yellow risk container. 
DNase/RNase free water Not dangerous waste 
TAE buffer (50x) 7152 Organic disposal without halogens 
TAE buffer (1x) Not dangerous waste 
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Protocol: BigDye
® 
Direct Cycle Sequencing Kit
2
  
 
Preparations and considerations 
 Remember that M13 PCR primers are a requirement using this method 
 Make sure that the Tetrad 2 Thermal Cycler (Bio-Rad) is available for use 
 For optimal performance, do not freeze and thaw the BigDye
®
 Direct Sequencing Master Mix 
more than five times 
 Make sure that the level of POP-7
™
 polymer is sufficient for your sample analyses 
 PROTECT the capillaries from drying (if they dry, they die) 
 
STEP 1: PCR amplification 
1.1) For each reaction, mix the components as displayed in table 1 in a MicroAmp
™
 Optical 96-Well 
Reaction Plate with Barcode. Use 1,0 µl DNase/RNase free water instead of genomic DNA to include 
negative controls.  
 
Table 1: Component concentrations and volumes required to PCR amplify one sample 
Components Volume 
Genomic DNA (5 ng/µl) 1,0 μl 
M13-tailed Fwd PCR primer (0,8 
µM) 
0,75μl 
M13-tailed Rev PCR primer (0,8 
µM) 
0,75 μl 
BigDye
®
 Direct PCR Master Mix 5,0 μl 
DNase/RNase free water 2,5 μl 
Total volume for each reaction 10,0 μl 
 
1.2) Mix the components well by pipetting up and down, seal the plate with caps  
       (Domed Cap Strip, Thermo Scientific) and centrifuge the reaction plate briefly 
1.3) Run the PCR amplification in a thermal cycler as displayed in table 2 
                                                 
2
 The BigDye
®
 Direct Cycle Sequencing Kit protocol may be downloaded from 
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_091370.
pdf  
 92 
 
Table 2: Time and temperature conditions during PCR amplification  
Stage 
Tetrad 2 Thermal Cycler (Bio-Rad) 
Temp Time 
Hold 96°C 5 min 
Cycle 
(35 cycles) 
94°C 30 sec 
63°C* 45 sec 
68°C 45 sec 
Hold 72°C 2 min 
Hold 4°C ∞ 
* Annealing temperatures depend on the PCR primer Tm values 
 
STEP 2: Agarose gel electrophoresis (optional) 
2.1) Prepare an 1,5% agarose gel (table 8) 
2.2) Mix 2,0 µl PCR-product and 2,0 µl gel loading buffer and load the entire volume into a  
         gel well 
2.3) Load 2,0 µl DNA ladder into the necessary number of gel wells 
2.4) Electrophoresis: 200 V for 30 min 
2.5) Use the GeneGenius Bio Imaging System for visualization 
 
Stopping point 1: PCR products can be stored at 4°C over night or at –15°C or  
–25°C for long-term storage. 
 
STEP 3: Cycle sequencing 
3.1) For each reaction, mix the components as displayed in table 3. Mix well and centrifuge the tubes 
briefly. Keep the premix on ice and in the dark using aluminum foil to avoid fluorescence bleaching. 
 
Table 3: Sequencing reaction mix components and volumes required to cycle sequence one sample 
Components Volume for each reaction 
BigDye
® 
Direct Sequencing Master Mix 2,0 μl 
Sequencing primer: 
• BigDye® Direct M13 Fwd Primer or 
• BigDye® Direct M13 Rev Primer  
1,0 μl 
Total volume for each reaction 3,0 μl 
 
3.2) Add 3,0 µl sequencing reaction mix to each sample 
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3.3) Seal the plate with caps and centrifuge the plate briefly 
3.4) Run the sequencing reactions in a thermal cycler as displayed in table 4 
 
Table 4: Time and temperature conditions during cycle sequencing 
Stage 
Tetrad 2 Thermal Cycler (Bio-Rad) 
Temp Time 
Hold 37°C 15 min 
Hold 80°C 2 min 
Hold 96°C 1 min 
Cycle 
(25 cycles) 
96°C 10 sec 
50°C 5 sec 
60°C 4 min 
Hold 4°C ∞ 
 
Stopping point 2: The reaction plate can be stored at 4°C over night, or at –15°C or  
–25°C for long-term storage. 
 
STEP 4: Purify the sequencing products 
Remember to keep the reaction plates in the dark to avoid fluorescence bleaching 
4.1) Centrifuge the reaction plate at 100 x G for 1 min 
4.2) Premix the SAM
™
 Solution and XTerminator
™
 Solution as displayed in table 5 
        
Before using the BigDye
®
 XTerminator
™
 Purification Kit
3
:  
 Make sure there are no particles in the SAM™ Solution. Heat the solution to 37°C and 
resuspend the solution if particles are present.  
 Homogenize the XTerminator™ Solution using a high-speed vortexer for 10 sec. Avoid 
pipetting from the top of the liquid due to rapid sedimentation 
 Use a sterile scalpel and cut the pipette tips to create wide-bore tips  
              (orifice > 1,0 mm) to aspirate the XTerminator
™
 Solution 
 Calculate to use 15% more of the SAM™ and XTerminator™ Solution than needed by the 
number of samples to be purified through dead volume. The ratio of SAM
™
 and 
XTerminator
™
 Solution should be 4,5:1 (v/v). 
                                                 
3 The BigDye
®
 XTerminator
™
 Purification Kit protocol may be downloaded from 
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/cms_042772.
pdf 
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Table 5: BigDye® XTerminator™ Purification Kit components and volumes to purify 96 samples  
Components Volume for each well Volume for 96 wells 
SAM
™
 Solution 45 µl 4968 µl 
XTerminator
™
 Solution 10 µl 1104 µl 
Total volume 55 µl 6072 µl 
 
4.3) Add 55 µl of the SAM
™
 and XTerminator
™
 Solution premix to each sample.  
        Mix the solution in between to prevent bead sedimentation. Cap seal the plate.  
4.4) Vortex the reaction plate for 30 min at 2000 rpm 
4.5) Centrifuge the reaction plate at 1000 x G for 2 min 
 
Stopping point 3: Sealed reaction plates can be stored up to 48 hours in room temperature or up to 10 
days at 4°C or –20°C before proceeding with capillary electrophoresis.  
Short protocol: BigDye
®
 Direct Cycle Sequencing Kit 
Plate ID Forward: 
Plate ID Reverse: 
Fragment sequenced: 
     PCR mix 
     Component Volume pr reaction 
(μL) 
Volume for 96 wells 
(μL) 
Genomic DNA (5 ng/μl) 1.0  
M13 Fwd PCR Primer (0,8 μM)  0.75 78.0 
M13 Rev PCR Primer (0,8 μM)  0.75 78.0 
BigDye
®
 Direct PCR Master Mix 5.0 520 
DNase/RNase free water  2.5 260 
Total volume pr reaction 10.0 936 μL/104 = 9 μL 
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Sequencing mix 
 
FORWARD REVERSE 
Component 
Volume 
(μL) 
Volume for 
 96 wells (μL) 
Volume for  
96 wells (μL) 
BigDye® Direct Sequencing                    
Master Mix 
2.0 216  216  
Sequencing primer:     
 
• BigDye® Direct M13 Fwd Primer 
or 1.0 
108  108  
• BigDye® Direct M13 Rev Primer 1.0 
 
 
Total volume pr reaction 3.0 324 µl/108 = 3 μl 324 µl/108 = 3 μl 
 
 
FORWARD REVERSE 
       
BigDye
®
 XTerminator
™
 Purification Kit 
Component Volume (μL) 
Volume for 96 wells 
(μL) 
SAM™ Solution 45 4968 
XTerminator®Solution 10 1104 
Total volume pr reaction 55 6072 
 
 
Agarose gel (1,5%) 
 Component Amount 
Agarose (BioRad, Cat.nr: 161-3102) 5,25 g 
TAE buffer (1x) to 350 ml 
GelRed Nucleotid Acid Stain                                   
(Biotinum, Cat.nr: 41003-1) 
35,0 μl 
 
 
Additional reagents 
50x TAE buffer  
Chemicals 
Trizma
®
 base, Sigma-Aldrich
®
 Norway AS (Prod. No. T1503) 
EDTA disodium salt, BDH
®
 (Prod. 100935V) 
Glacial Acetic Acid, MERCK (Cat. No. 100063) 
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Procedure 
Table 6: Component volumes and amounts to make 1 litre of TAE buffer (50x) 
Components Amount  R/H and S/P sentences 
Trizma
®
 base  242 g H315/319/335, P261/305+351+338 
EDTA disodium 
salt 
100 ml 0,5 M EDTA (pH = 
8,0) 
R36/52/53, S61 
Glacial Acetic 
Acid  
57,1 ml H226/314, P280/305+351+338/310 
MQ-water  up to 1000 ml - 
 
1) Scale in 242 g Trizma
® 
base 
2) Add 500 ml MQ-water 
3) Add 100 ml 0,5 M EDTA (pH = 8,0) and 57,1 ml Glacial Acetic Acid 
4) Add MQ-water to adjust to 1000 ml 
Store the buffer in room temperature 
 
1x TAE buffer  
Procedure 
Table 7: Component volumes to make 1 litre of TAE buffer (1x) 
Components Amount  R/H and S/P sentences 
TAE buffer 
(50x) 
100 ml Xi; R36/38/43/52/53, S24/26/37/61 + P338 
MQ-water  up to 1000 ml - 
Store the buffer in room temperature 
 
Agarose gel (1,5% agarose) 
Chemicals 
Agarose, Bio-Rad Laboratories (Cat. No. 161-3102) 
GelRed™ Nucleotid Acid Stain, Biotium (Cat. No. 41003-1) 
1x TAE buffer  
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Procedure 
Table 8: Component volumes and amounts to make an 1,5% agarose gel  
Components Amount  R/H and S/P sentences 
Agarose  5,25 g - 
TAE buffer (1x)  350 ml - 
GelRed
™
 NucleicAcid Stain 35,0 µl Xi; R36/37/38, 
S23/26/36 
 
1) Put together the gel chamber and place the gel well combs 
2) Mix 5,25 g Agarose and 350 ml 1x TAE buffer in an Erlenmeyer flask 
3) Heat to boiling in a microwave 
4) Swirl the flask gently until all the agarose is completely dissolved 
5) Cool the gel solution to about 65°C 
6) Add 35,0 µl GelRed
™
 Nucleotid Acid Stain (Biotium) 
7) Pour the gel in the gel chamber and let it harden for about 30 min 
8) Remove the combs and clean the combs and chamber using tap water 
Store the gel by 4°C. Wrap the gel in plastic foil to avoid drying. 
 
Gel loading buffer (0,1% Bromophenol blue)  
Chemicals 
Bromophenol blue, Bio-Rad Laboratories (Cat. No. 161-0404) 
Ficoll
®
 PM 400, Sigma-Aldrich
®
 Norway AS (Prod. No. F4375) 
1x TAE buffer  
 
Procedure 
Table 9: Component volumes and amounts to make 0,1% Bromophenol blue gel loading buffer 
Components Amount  R/H and S/P 
sentences 
Bromophenol blue  0,025 g S22/24/25 
Ficoll
®
 PM 400  5,0 g - 
1x TAE buffer  25 ml - 
 
1) Scale in 0,025 g Bromophenol blue and 5,0 g Ficoll in a 50 ml tube  
2) Add 25 ml 1x TAE buffer 
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3) Ficoll needs time to dissolve properly. Vortex the tube for about 24 hours to  
    get a homogenous solution 
Keep the buffer in room temperature for short-term storage, and by 4°C for long-term storage 
 
1x Sequencing buffer  
Chemicals 
10x 3730 Buffer with EDTA, Applied Biosystems (Part. No. 4335613) 
 
Procedure 
Table 10: Component volumes to make 1 litre of Sequencing buffer (1x) 
Components Amount  R/H and S/P 
sentences 
10x 3730 Buffer with EDTA 100 ml - 
MQ-water  up to 1000 ml - 
Store the buffer at 4°C 
 
Xi = irritant. R36: Irritating to eyes. R37: Irritating respiratory system. R38: Irritating to skin. 
R43: May cause sensitization by skin contact. R52: Harmful to aquatic organisms. R53: May 
cause long-term adverse effects in the aquatic environment. H226: Flammable liquid and 
vapor. H314: Causes severe skin burns and eye damage. H315: Causes skin irritation. H319: 
Causes serious eye irritation. H335: May cause respiratory irritation.  
S22: Do not breathe dust. S23: Do not breathe gas/fumes/vapor/spray. S24: Avoid contact 
with skin. S25: Avoid contact with eyes. S26: In case of contact with eyes, rinse immediately 
with plenty of water and seek medical advice. S36: Wear suitable protective clothing. S37: 
Wear suitable gloves. S61: Avoid release to the environment. Refer to special 
instructions/safety data sheet. P261: Avoid breathing dust/fume/gas/mist/vapor/spray. P280: 
Wear protective gloves/protective clothing/eye protection/face protection. P310: Immediately 
call a POISON CENTER or doctor/physician. P338: Remove contact lenses if present and 
easy to do and continue rinsing. P305+351+338: IF IN EYES: Rinse continuously with water 
for several minutes. Remove contact lenses if present and easy to do and continue rinsing. 
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Appendix D 
Principle of the Neon Transfection system (Invitrogen, USA) 
The Neon
TM
 tips contain a gold-plated electrode and works as an electroporation chamber by 
delivering a high electrical field to a biological sample. The advantage of this equipment 
compared to standard cuvette based electroporation, is that the gap size between the 
electrodes becomes larger, while the surface area of each electrode becomes smaller. The 
consequences are uniform electrical field, less ion formation, minimal PH changes and 
negligible heat changes.  Different types of samples such as nucleic acids, proteins and siRNA 
can be transfected into all mammalian cell types. Together with this system Neon
TM
 Kits (2 
formats: 10 µl or 100 µl sample (Invitrogen) with reagents and pipette tips are used for the 
transfections. The cell counts pr. reaction are between 1x10
4
 -5x10
6 
and the sample volume 
varies between 10 µl -100 µl. The system can be combined with various culture plate formats 
(60mm, 6-well, 48-well and 24 well).                                                                  
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Appendix E 
 
Table E1. Observations and numbers of bacterial colonies containing sample- and control plasmids after 
the first performed mutagenesis on the LB agar plates.  
Plasmid Description +: With X-Gal and IPTG 
-: Without X-Gal and IPTG 
Results 
 
pWhitescript  Mutagenesis 
control 
+ Negative (only one 
colony) 
PIK3CA P110 S405F Sample  + Fewer number of 
white colonies 
PIK3CA P110 S405F  Sample - Many white 
colonies 
PUC18  
 
Transformation 
control 
+ 
 
Average of total 
number of 
colonies: 38. 
Average of number 
of blue colonies: 
17. 
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Table E2. Observations and numbers of bacterial colonies containing sample- and control plasmids after 
the second performed mutagenesis of the LB agar plates.  
 
Plasmid Description +: With X-Gal and IPTG 
-: Without X-Gal and IPTG 
Results 
 
pWhitescript Mutagenesis control + Many blue colonies 
TP53 A120G Sample + White, separate 
colonies, fewer 
than the LB agar 
plate without X-gal 
and IPTG 
TP53 A120G Sample - White, separate 
colonies 
TP53 A179G Sample + White, separate 
colonies, fewer 
than the LB agar 
plate without  X-
gal and IPTG 
TP53 A179G Sample - White, separate 
colonies 
TP53 WT WT control - Many white 
colonies 
PIK3CA P110 
WT (plenti 6.3) 
WT control - Many white 
colonies 
 
PIK3CA P110 
E545K (Plenti 
6.3)  
Mutant control - Many white 
colonies 
LacZ (Plenti 
6.3) 
Normal control - Many white 
colonies 
PUC18 Transformation 
control 
+ -Total number of 
colonies: ~86 
-Number of blue 
colonies: ~24 
 
On both mutagenesis the X-gal concentration was 0,005 % instead of 2% which is the 
protocol recommends. This is a possible reason why it was < 90% blue colonies on the 
PUC18 transformation control.  
 
 
 
